{ "schemaVersion": "deck-intelligence.v1", "id": "019dd923-5ca1-7489-b638-42055a53b541", "slug": "1774c324fda45105", "title": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report", "subtitle": "L.E.K.", "author": "L.E.K.", "pageCount": 58, "kind": "consulting-deck", "orientation": "landscape", "aspectRatio": 1.778, "document": { "id": "019dd923-5ca1-7489-b638-42055a53b541", "slug": "1774c324fda45105", "title": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report", "rawTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report", "authorId": "LEK", "authorName": "L.E.K.", "authorDisplay": "L.E.K.", "kind": { "slug": "consulting-deck", "label": "Consulting deck" }, "sourceType": { "slug": "strategy_consulting", "label": "Strategy consulting" }, "fileName": "Pivoting-to-a-High-Quality-Growth-of-Clinical-Trials-in-China-PharmaDJ-x-L.E.K.-Clinical-Development-Report.pdf", "sourceUrl": "https://www.lek.com/sites/default/files/PDFs/china-clinical-trials.pdf", "sourceDate": "2022-11-11 00:00:00", "presentationDate": null, "ingestedAt": "2026-04-23 20:51:38+00", "status": "ready", "pageCount": 58, "orientation": "landscape", "aspectRatio": 1.778, "targetCompany": null, "targetTicker": null, "metadata": { "local_root": "/tmp/legacy-images/1774c324fda45105", "origin_corpus": "consulting" } }, "coverage": { "pageCount": 58, "pagesIndexed": 58, "pagesWithImages": 58, "pagesWithMetadata": 58, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 364, "chartCount": 25, "metricSlides": 23, "toolMatches": 12, "documentToolMatches": 0, "frameworkMatches": 8, "arcMatches": 1, "beatMatches": 3, "loopMatches": 1, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": true, "reviewAvailable": true, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "evidence": "The report follows a logical structure, starting with an overview of the situation, followed by a discussion of the complications, and concluding with a proposed solution.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:14:56.16858+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 5, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 1, "name": "Situation & Context", "beatId": "d4acf7a6-2c83-4ad1-87b2-d5cc913d92fe", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Situation & Context", "slug": "consultants-gambit-situation-context", "status": "active", "canonId": "019dd9b8-05ae-741b-992d-65ee83c639b3", "version": 1, "description": null }, "evidence": "The report provides an overview of the clinical trials landscape in China, including key economic and healthcare indexes.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 11, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 6, "name": "Problem & Complication", "beatId": "2e308d53-f564-4d1b-a207-755a279e3246", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Problem & Complication", "slug": "consultants-gambit-problem-complication", "status": "active", "canonId": "019dd9b8-064a-777f-a374-e9a8c43dedd4", "version": 1, "description": null }, "evidence": "The report discusses the challenges facing China's clinical development, including COVID-19 uncertainties and funding challenges.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 20, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 12, "name": "Solution & Approach", "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Solution & Approach", "slug": "consultants-gambit-solution-approach", "status": "active", "canonId": "019dd9b8-071c-7161-9184-580fdac7a4f9", "version": 1, "description": null }, "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f", "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.", "position": 0, "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:14:56.308784+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "10aef478-7ed9-4b21-b714-178a7d6e35c7", "evidence": "The slide is titled 'Pivoting to a High Quality Growth of Clinical Trials in China' and has a title/headline, subtitle/subtitle, and image/logo, which are typical components of a cover slide.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:53:07.796298+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4b8481c7-3cc2-4e12-9710-c256f20f8c7d", "evidence": "Foreword summarizing key strategic trends", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:15:57.064283+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 2, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3cea0ef1-d153-49fc-9265-df97b06090fa", "evidence": "Executive summary of future strategic trends", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:15:57.132817+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7774e5cf-48b2-4f7d-8ad5-834194f488b5", "evidence": "Agenda items listed", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:15:57.206645+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "1967d4a3-e3d4-40f5-b017-01a0e0a92f89", "evidence": "Opportunities and challenges of China healthcare market", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:15:57.067773+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "88d8805a-9b08-431b-8523-9594c15adf24", "evidence": "chart/bar-vertical: Number of newly started clinical trials in China (2016-21)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:15:57.190951+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "d87fad6b-0c9b-45b6-bf4c-46a182e83faa", "evidence": "list/bullet: Key drivers: Favorable policy, Accelerated innovative drug development, Continuous R&D investment", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:15:57.151545+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "14957684-3318-45b3-a029-fb08dcbf04c2", "evidence": "chart/bar-stacked: Number of newly started clinical trials by trial phase (China)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:15:57.351196+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "51baa571-7733-403a-95a5-92375c7d2dd3", "evidence": "list/bullet: Strong growth of trial number in China has been fueled particularly by development of innovative drugs.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:15:57.311279+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "436dd1af-d7d9-47b6-a8dd-021cc1911876", "evidence": "list/bullet: Regulatory pressure: Stringent R&D requirements such as potential head-to-head trial for oncology drug; Price and profit cutdown brought by VBP and NRDL negotiation", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-16 21:14:35.553184+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1e6eb92b-34c4-4f5a-af5c-47d6ed881471", "evidence": "list/numbered: 01 Development of More Innovative and Differentiated Therapies", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-16 21:14:35.689086+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "af95a5d1-ae9f-4241-ae12-e251101256d8", "evidence": "The components list several potential solutions or areas of focus for drug development, such as discovering new targets, improving drug features, and investing in cutting-edge technology platforms, which indicates a problem statement or areas for improvement.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-16 21:14:26.1249+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "5304dc4b-e89a-4ad9-8fae-8d46c5d323a5", "evidence": "Categorization of market factors into Policy, Economy, Society, and Technology.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 19:22:37.738+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "PEST" }, { "matchId": "1f4e6984-0a6f-46f8-9e35-b21b5bd44395", "evidence": "Use of direct quotes from industry experts to support the quantitative data.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 19:22:39.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "testimonial" }, { "matchId": "027a0d0b-5eb2-4678-ad73-e7c995e3c223", "evidence": "Contrasts 'Past' (quick launch) with 'Future' (commercial attractiveness) to show strategic evolution.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 19:22:41.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "frameworkName": "before-after-framing" }, { "matchId": "1ab21dee-cc19-462c-8204-674faba03cd8", "evidence": "The slide presents a chronological progression of events across three distinct time periods.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 19:22:43.437+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "frameworkName": "timeline" }, { "matchId": "d4244693-e451-4d75-ae1a-4b93904335a4", "evidence": "Chronological progression of regulatory guidelines", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 19:22:43.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 35, "frameworkName": "timeline" }, { "matchId": "42218049-4531-4792-9b10-6900ea288852", "evidence": "The slide explicitly contrasts drivers vs barriers in a side-by-side layout.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 19:22:42.812+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "comparison_frame" }, { "matchId": "08610041-4b18-4155-b1af-91454a90bf4d", "evidence": "Circular flow diagram representing a two-way mutually reinforcing relationship.", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 19:22:47.258+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "frameworkName": "flywheel" }, { "matchId": "585bb3fd-2899-44da-a03c-03f9b22fb002", "evidence": "Chronological presentation of events on a horizontal axis.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 19:22:43.884+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 45, "frameworkName": "timeline" } ], "patterns": [] }, "storymakers": null, "score": { "backend": "claude", "scoredAt": "2026-05-02 07:10:52.207+00", "subScores": { "scqa_arc": 72, "action_titles": 88, "mece_structure": 75, "closing_strength": 58, "evidence_quality": 85, "clarity_of_thesis": 85, "production_quality": 75, "visual_storytelling": 70 }, "totalScore": 76, "coveragePct": 100, "explanations": { "scqa_arc": "Solid Situation (S5-10 market foundation) → Complication (S11, S18 headwinds & homogeneous competition) → Answer (S14 four trends, then S16-46 elaboration); the Question is implicit rather than explicit and the analytical mass tilts heavy.", "action_titles": "Near-universal full-sentence insight titles throughout content slides; e.g., S7 'China clinical trial has experienced rapid growth over the past five years, driven by favorable policy...' — only S24 and S31 fall back to topic labels in the slide title (though their action titles still carry the insight).", "mece_structure": "Four strategic-trend pillars (innovation/differentiation S16-22, commercial attractiveness S24-28, smart/digital S30-37, globalization S39-46) are clearly demarcated by repeating agenda slides, with mild overlap between commercial attractiveness and innovation themes.", "closing_strength": "S48 ('Industry can support and lead this transformation') poses open strategic questions rather than concrete recommendations or next steps; subsequent S49-58 are appendix/contact, so the deck ends without a crisp call to action.", "evidence_quality": "Claims are consistently backed by survey data (N=101, methodology disclosed S50), CAGR figures, FDA-designation counts (S17), licensing-deal tables (S44), and triangulating expert quotes; very few unsupported assertions.", "clarity_of_thesis": "Slide 3 declaratively states the central thesis ('Future China clinical trials will pivot to high quality growth under four main strategic trends'), echoed in cover (S1) and foreword (S2).", "production_quality": "High action-title density, consistent L.E.K. branding, disciplined footnotes and methodology disclosure (S50-51), and a glossary (S52); main weakness is overcrowded data density on most analytical slides.", "visual_storytelling": "Good range — PEST framework (S6), timelines (S31/S35/S45), comparison tables (S5/S30), stacked bars and big-number callouts (S33) — but ~20 slides are flagged density=overcrowded, diluting message-per-slide clarity." }, "slidesAnalyzed": 58 }, "review": { "backend": null, "verdict": "A competent, survey-driven thought-leadership report with a clear four-pillar spine and numerate titles, but it builds analytically and then fails to land — use its Act 1 setup (pp.3, 5-12) as a teaching example of thesis-plus-proof, not its resolution.", "reviewedAt": "2026-04-25 02:21:59+00", "slidesSeen": 58, "suggestions": [ "Expand p.48 into a proper resolution act: 3-5 slides with prioritized actions per audience (domestic biopharma, MNC, regulator) tied back to each of the four trends.", "Rewrite agenda slides with pillar-level action titles (e.g. 'Pillar 2: Prioritize TAs by commercial attractiveness, not scientific heat') so each divider carries the insight.", "Tighten long subordinate-clause titles into single declarative sentences with a verb and a number (e.g. p.22, p.28) and cut or merge non-insight slides.", "Replace the closing 'Connect with us' / firm credentials tail with a one-page call-to-action summary that restates the four pivots and the decisions each reader must make next." ], "closingScore": 38, "openingScore": 62, "topStrengths": [ "Thesis is named early and repeated as the spine: 'pivot to high-quality growth' appears on p.3 exec summary and again on p.12 as the hinge.", "Strong use of survey-derived numeric proof points in titles (p.12 60%, p.20 70%, p.33 71%, p.40 95%) gives the narrative quantitative backbone.", "Clear four-pillar structure (innovation differentiation, TA prioritization, digitalization, globalization) with dedicated section agendas.", "Good SCQA micro-structure within Act 1: growth story (pp.5-10) → headwinds (p.11) → resolution hook (p.12)." ], "topWeaknesses": [ "Resolution act is effectively one slide (p.48) — no prioritized recommendations, no 'so what for pharma X' translation, and no decision framework.", "Closing 10 slides (pp.49-58) are pure methodology + firm marketing + disclaimer, so the deck trails off rather than lands.", "Nine agenda slides (pp.4, 13, 15, 23, 29, 38, 47, 49, 53) with no differentiated pillar labels read as navigation clutter, not MECE pillars.", "Several titles are analytical observations rather than insights with implications — e.g. p.24 'Oncology has become the most heated TA' begs the 'therefore what?' that never lands.", "Pain points slide (p.11) is sparse and under-developed given it carries the complication for the whole narrative." ], "narrativeScore": 68, "pillarCritique": "Repeated 'Agenda' slides (pp.4, 13, 15, 23, 29, 38, 47, 49, 53) act as section dividers and loosely map to the four trends plus methodology/credentials — MECE-ish in intent but unlabeled in the inventory, so pillars read as topic dumps ('Innovation', 'TA focus', 'Digitalization', 'Globalization') rather than insight-bearing pillar statements.", "closingCritique": "The pre-appendix close is a single vague imperative on p.48 ('Industry can support and lead this transformation') with no prioritized actions, owners, or decisions; pp.49-58 devolve into methodology, acknowledgements, firm credentials, and a 'Connect with us' slide — an appendix dump, not a memorable close.", "openingCritique": "The Executive Summary (p.3) does lead with the thesis ('pivot to high quality growth under four strategic trends'), but pp.1-2 and the agenda (p.4) dilute the hook, and the first real content slide (p.5) opens with macro indexes rather than the stakes for the reader's R&D decisions.", "extractionSeconds": 59.036926, "narrativeCritique": "The deck follows a coherent S-C-A sequence — setup (pp.5-10 growth foundation), complication (p.11 headwinds), and analytical build around four trends (pp.14-46) — but the resolution act collapses into a single slide (p.48 'Industry can support and lead this transformation') with no concrete recommendation, so the arc ends more as a survey report than a call to action.", "titleQualityScore": 74, "titleQualityCritique": "Most titles are genuinely declarative and insight-bearing — e.g. p.18 'past innovation mainly concentrated around heated targets, leading to rising concern of homogeneous competition' and p.40 '95% of respondents either conducted or expressed interest in ex-China clinical trials' — but several lapse into topic labels (p.22 'companies are also considering to tackle through discovering new targets...', p.28 'Other factors considered for drug prioritization...') and titles are often long and clause-heavy rather than tight action statements." }, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/R-ImTecPvJcaxWt6zKWVBXW4ZXuXbE_s81RPchLylkc/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xNzc0YzMyNGZkYTQ1MTA1L3AwMDEuanBn", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 6, "textChars": 475, "nDataPoints": 0, "notes": null, "elementsJson": [ "logo_grid", "photo" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "at": "2026-07-17 03:24:01.136+00", "seconds": 2.457, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/1", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-1", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.35, "x": 0.037, "y": 0.88 }, "kind": "disclaimer", "text": "These materials are intended to supplement a discussion with L.E.K. Consulting. These perspectives will, therefore, only be meaningful to those in attendance. The contents of the materials are confidential and subject to obligations of non-disclosure. Your attention is drawn to the full disclaimer contained in this document.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": "disclaimer", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:01.136+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "76b1db72-5efc-4e77-a4ce-8886366c7c82", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.55, "x": 0.037, "y": 0.06 }, "kind": "image", "text": "LEK PharmaDJ CHINATRIALS 14", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:01.136+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a588a895-dda9-473e-b514-8956e223b0f9", "parentComponentId": null }, { "bbox": { "h": 0.86, "w": 0.5, "x": 0.5, "y": 0.14 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:01.136+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b2a35f75-2aa1-4baf-a1be-55d63366bcc7", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.15, "x": 0.037, "y": 0.605 }, "kind": "paragraph", "text": "11 November 2022", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:01.136+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d67d248f-dd0c-4905-b2a6-5c9891ecbd8b", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.39, "x": 0.037, "y": 0.515 }, "kind": "subtitle", "text": "PharmaDJ x L.E.K. Clinical Development Report", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:01.136+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eee99dc1-e6aa-431f-8878-df8b9f7e9bd5", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.39, "x": 0.037, "y": 0.425 }, "kind": "title", "text": "Pivoting to a High Quality Growth of Clinical Trials in China", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:01.136+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "342d2be1-a2f3-4de7-86fa-628d8df19cb4", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "10aef478-7ed9-4b21-b714-178a7d6e35c7", "evidence": "The slide is titled 'Pivoting to a High Quality Growth of Clinical Trials in China' and has a title/headline, subtitle/subtitle, and image/logo, which are typical components of a cover slide.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:53:07.796298+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 1, "name": "Situation & Context", "beatId": "d4acf7a6-2c83-4ad1-87b2-d5cc913d92fe", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Situation & Context", "slug": "consultants-gambit-situation-context", "status": "active", "canonId": "019dd9b8-05ae-741b-992d-65ee83c639b3", "version": 1, "description": null }, "evidence": "The report provides an overview of the clinical trials landscape in China, including key economic and healthcare indexes.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/Y2rKpA3oNJ5znzZAqRsifgnHR4TmqbUB_WJmSea6Xr4/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xNzc0YzMyNGZkYTQ1MTA1L3AwMDEuanBn", "imagePathAlt": "https://imgproxy.kitesheet.com/ZMpKb05cMIfZo_4gm_duNvx2IStTsKQ62TWI5EvKIC0/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xNzc0YzMyNGZkYTQ1MTA1L3AwMDEucG5n", "thumbSrcAlt": "https://imgproxy.kitesheet.com/dUMgfj3yPSIq9aBlNMyWx_W_F-JcWni44ED21PFuH0M/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8xNzc0YzMyNGZkYTQ1MTA1L3AwMDEucG5n" }, { "page": 2, "type": "setup", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 37, "componentCount": 2, "textChars": 1291, "nDataPoints": 0, "notes": null, "elementsJson": [ "paragraph", "bullet_list" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:39.766+00", "seconds": 5.067, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/2", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-2", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "list", "text": "China clinical development has experienced robust growth over the past 5-10 years. However, much of drugs developed are caught in homogeneous competition which is expected to be increasingly unsustainable going forward. With more companies starting to tackle the situation, the transformation from extensive growth to quality growth of clinical trials in China is expected.\n\nWith this as background, the report, Pivoting to a High Quality Growth of Clinical Trials in China, published in collaboration with PharmaDJ, provides a comprehensive overview of the clinical development trends in China with key insights from executives across the pharmaceutical ecosystem\n\nSupported with executive management interviews and survey, the report may serve as a starting point for different types of pharmaceutical companies, including multinational pharmas, Chinese biopharmas and biotechs, and CROs, to rethink about how to get well-prepared for the future drug R&D through being more innovative, more commercially attractive, smarter and more efficient as well as more internationalized and cooperative", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.766+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3556e26e-0fdd-48ab-9a79-7a30939eb0ca", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.06 }, "kind": "title", "text": "Foreword: This report summarizes the key strategic trends of clinical development in China, and can be referenced by pharmaceutical companies to support their drug R&D considerations and strategies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.766+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "113a73f8-e276-4696-97ce-4d88862d7f5d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4b8481c7-3cc2-4e12-9710-c256f20f8c7d", "evidence": "Foreword summarizing key strategic trends", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:15:57.064283+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 2, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 1, "name": "Situation & Context", "beatId": "d4acf7a6-2c83-4ad1-87b2-d5cc913d92fe", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Situation & Context", "slug": "consultants-gambit-situation-context", "status": "active", "canonId": "019dd9b8-05ae-741b-992d-65ee83c639b3", "version": 1, "description": null }, "evidence": "The report provides an overview of the clinical trials landscape in China, including key economic and healthcare indexes.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 3, "type": "setup", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 3, "textChars": 2136, "nDataPoints": 0, "notes": null, "elementsJson": [ "headline_text", "bullet_list", "paragraph" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:42.252+00", "seconds": 7.537, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/3", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-3", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.9, "x": 0.05, "y": 0.3 }, "kind": "list", "text": "Development of More Innovative and Differentiated Therapies: Chinese pharmas have surely made some progresses in innovation in the past few years; however, many are concentrated around heated targets (such as PD-1, EGFR), leading to homogeneous competition. With companies starting to focus on new modalities, technology platforms and targets, more innovative and differentiated therapies are expected.\nIncreasing Focus of More Commercially Attractive Development Areas: Oncology has become the most heated TA for clinical development in China over the past few years. In the future, companies tend to consider more comprehensively when prioritizing drugs for R&D with commercial attractiveness being more of a key consideration. Other factors considered also include return on investment, company expertise, and feasibility to collaborate.\nAdoption of Smarter Clinical Trial Tools: As increasing complexity becomes the mega trend of clinical trial, demands for smart and digital tools are rising. Technologies such as EDC, CTMS, eTMF and PVS have already being widely adopted in China clinical trials. It is believed that smart and digital tools will be indispensable for future clinical trial, and revolutionary impact may even be witnessed.\nA Two-way Pursuit – Globalization of Chinese Biopharma & Evolution of MNC China R&D strategy: Globalization is increasingly an imperative for Chinese biopharmas and in order to succeed in oversea trial, careful prioritization of destination, oversea local team setup, and active communication with regulatory agencies are anticipated; With Chinese innovations being validated on the global stage, MNCs also tend to strengthen the cooperation with Chinese counterparts through license-in and incubation.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.252+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "939b306b-5321-4a6a-adb9-f50a4ab9fa32", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "paragraph", "text": "Though faced with challenges, the foundation for China healthcare market is still strong, which is expected to support the future high-quality growth of China clinical trial. Four strategic trends are anticipated as China clinical trial development pivoting to quality growth:", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.252+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1a369286-6c8d-4233-b53a-610a41d23731", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Executive summary: Future China clinical trials will pivot to high quality growth under four main strategic trends", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.252+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "90101306-edc3-4ab2-bf1c-600d74fca075", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "3cea0ef1-d153-49fc-9265-df97b06090fa", "evidence": "Executive summary of future strategic trends", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 03:15:57.132817+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 1, "name": "Situation & Context", "beatId": "d4acf7a6-2c83-4ad1-87b2-d5cc913d92fe", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Situation & Context", "slug": "consultants-gambit-situation-context", "status": "active", "canonId": "019dd9b8-05ae-741b-992d-65ee83c639b3", "version": 1, "description": null }, "evidence": "The report provides an overview of the clinical trials landscape in China, including key economic and healthcare indexes.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 4, "type": "setup", "function": "front_matter", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 8, "componentCount": 2, "textChars": 178, "nDataPoints": 0, "notes": null, "elementsJson": [ "headline_text", "bullet_list" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:38.231+00", "seconds": 3.499, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/4", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-4", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.502, "w": 0.498, "x": 0.038, "y": 0.218 }, "kind": "list", "text": "Context of clinical trial development in China\nFuture strategic trends of clinical trial development in China\nNext step questions\nResources and references\nAbout the authors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:38.231+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "073911b7-83e8-4827-b2a4-ddfafedd74bd", "parentComponentId": null }, { "bbox": { "h": 0.044, "w": 0.106, "x": 0.038, "y": 0.144 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:38.231+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "44ede5f1-6b99-4bba-ad95-87cecd095e7a", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7774e5cf-48b2-4f7d-8ad5-834194f488b5", "evidence": "Agenda items listed", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:15:57.206645+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 1, "name": "Situation & Context", "beatId": "d4acf7a6-2c83-4ad1-87b2-d5cc913d92fe", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Situation & Context", "slug": "consultants-gambit-situation-context", "status": "active", "canonId": "019dd9b8-05ae-741b-992d-65ee83c639b3", "version": 1, "description": null }, "evidence": "The report provides an overview of the clinical trials landscape in China, including key economic and healthcare indexes.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 5, "type": "setup", "title": "The table is segmented into three thematic blocks: demographics, economic indicators, and healthcare market metrics.", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 9, "textChars": 777, "nDataPoints": 27, "notes": "The table is segmented into three thematic blocks: demographics, economic indicators, and healthcare market metrics.", "elementsJson": [ "headline_text", "comparison_table", "callout_box" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:37.779+00", "seconds": 3.038, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/5", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-5", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.1, "x": 0.89, "y": 0.71 }, "kind": "callout", "text": "3rd largest drug market", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "07971e6c-ecf8-4e63-b961-a4feeec55b8c", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.1, "x": 0.89, "y": 0.33 }, "kind": "callout", "text": "No.1 total & aged population", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aecaa0de-3c41-4dea-9315-f1de68cc48b6", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.1, "x": 0.89, "y": 0.51 }, "kind": "callout", "text": "Fast growing economy", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee6002e4-95a7-4803-aebf-aadf35bc9ec1", "parentComponentId": null }, { "bbox": null, "kind": "callout", "text": "No.1 total & aged population; Fast growing economy; 3rd largest drug market", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:58+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-3fc0495244e1", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Population: 1.4", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:58+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-40a78bf01b56", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.75, "x": 0.03, "y": 0.88 }, "kind": "source-note", "text": "Note: *GNI: Gross National Income; for EU health spending, data is for 2019 based on available public information; GDP refers to real GDP; GDP growth is forecasted by IMF on October 2022 Source: World Bank, United Nations, World Population Review, Grand View, International Monetary Fund, IQVIA, PharmExec, VBData, L.E.K. analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "be55d21e-777f-4345-a380-cb95b7624d05", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.84, "x": 0.05, "y": 0.31 }, "kind": "table", "text": "Comparison table of 9 metrics across 3 regions (China, U.S., EU)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "695e284a-8da1-4aeb-b16c-db02c352de88", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.94, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "Based on the key economic and healthcare indexes comparison of China, U.S., and European Union countries, China has a strong foundation for healthcare market growth", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "820a9e44-07aa-42eb-a50c-cac326462c82", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.03, "y": 0.21 }, "kind": "title", "text": "Key economic and healthcare indexes of China, U.S. and EU*", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.779+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0f9c88e8-456c-444e-8542-14882d42fabb", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Population", "numberRaw": "1.4", "numberKind": "plain", "actionTitle": "Based on the key economic and healthcare indexes comparison of China, U.S., and European Union countries, China has a strong foundation for healthcare market growth", "calloutText": "No.1 total & aged population; Fast growing economy; 3rd largest drug market", "numberScale": null, "numberValue": 1.4, "metricFamily": "other", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 1, "name": "Situation & Context", "beatId": "d4acf7a6-2c83-4ad1-87b2-d5cc913d92fe", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Situation & Context", "slug": "consultants-gambit-situation-context", "status": "active", "canonId": "019dd9b8-05ae-741b-992d-65ee83c639b3", "version": 1, "description": null }, "evidence": "The report provides an overview of the clinical trials landscape in China, including key economic and healthcare indexes.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Setup", "slug": "setup", "status": "active", "canonId": "019dd9b8-020e-7505-af9b-d9b9a4679bcc", "version": 1, "description": "Where the deck grounds the reader before doing anything else. Almost every arc opens here." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 6, "type": "analysis", "title": "Uses a PEST framework (Policy, Economy, Society, Technology) to structure the market analysis.", "function": "diagnose", "rawType": "market_landscape", "block": null, "metadata": { "slideType": "market_landscape", "slideTypeCanon": { "name": "Market landscape", "slug": "market_landscape", "status": "active", "canonId": "019de52d-0b6d-75db-a946-9ac362e3afc2", "version": 1, "description": null }, "function": "diagnose", "functionCanon": { "name": "Diagnose", "slug": "diagnose", "status": "active", "canonId": "019de52d-1657-7223-acc5-7437d878c850", "version": 1, "description": null }, "density": "balanced", "densityScore": 38, "componentCount": 5, "textChars": 540, "nDataPoints": 0, "notes": "Uses a PEST framework (Policy, Economy, Society, Technology) to structure the market analysis.", "elementsJson": [ "headline_text", "process_diagram", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:37.738+00", "seconds": 2.652, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/6", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-6", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.9, "x": 0.05, "y": 0.3 }, "kind": "framework", "text": "PEST Analysis (Policy, Economy, Society, Technology)", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.738+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "519a7cc7-a3e5-4474-80f2-fa3c8ea36e89", "parentComponentId": null }, { "bbox": null, "kind": "framework", "text": "PESTLE", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": { "name": "Structuring frame", "slug": "structuring-frame", "status": "active", "bestFor": null, "canonId": "019dd9e1-48ff-708d-8103-a8464743e560", "version": 1, "bodyDocId": null, "description": "A named scaffold for organising content (SCQA, situation-action-result, etc.).", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:58+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbb-efe15dc8be8d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.88 }, "kind": "paragraph", "text": "Note: *QoL: Quality of Life, CXO: Contract Organization, CRO: Contract Research Organization, CMO: Contract Manufacturing Organization\nSource: World Bank, United Nations, Centre for Economics and Business Research, L.E.K. analysis", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.738+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dcf2cf2f-a5c2-41c3-86a3-d8765fc8f3c9", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "China has and will continue to own the largest patient pool with better affordability, though facing several challenges such as price pressure, lack of patient awareness and cutting-edge innovation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.738+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bb06bb30-9540-4bae-ae8c-59db1596ed9e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.05, "y": 0.2 }, "kind": "title", "text": "Opportunities and challenges of China healthcare market", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.738+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "16e7a8d0-64f1-402e-b9d4-b304956790f5", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "1967d4a3-e3d4-40f5-b017-01a0e0a92f89", "evidence": "Opportunities and challenges of China healthcare market", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 03:15:57.067773+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "5304dc4b-e89a-4ad9-8fae-8d46c5d323a5", "evidence": "Categorization of market factors into Policy, Economy, Society, and Technology.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 19:22:37.738+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "PEST" } ], "arcBeats": [ { "to": 11, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 6, "name": "Problem & Complication", "beatId": "2e308d53-f564-4d1b-a207-755a279e3246", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Problem & Complication", "slug": "consultants-gambit-problem-complication", "status": "active", "canonId": "019dd9b8-064a-777f-a374-e9a8c43dedd4", "version": 1, "description": null }, "evidence": "The report discusses the challenges facing China's clinical development, including COVID-19 uncertainties and funding challenges.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 7, "type": "analysis", "title": "The slide uses a comparative bar chart structure to contrast high growth in China (29% CAGR) against stable growth in the U.S. (3% CAGR).", "function": "summarize", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 67, "componentCount": 7, "textChars": 728, "nDataPoints": 12, "notes": "The slide uses a comparative bar chart structure to contrast high growth in China (29% CAGR) against stable growth in the U.S. (3% CAGR).", "elementsJson": [ "headline_text", "bar_chart_vertical", "icon_grid", "bullet_list", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:41.225+00", "seconds": 6.106, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/7", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-7", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "China clinical trial has experienced rapid growth over the past five years, driven by favorable policy, accelerated innovative drug developed, and continuous R&D investment.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:58+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-05829439d7c5", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.42, "x": 0.04, "y": 0.22 }, "kind": "chart", "text": "Number of newly started clinical trials in China (2016-21)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.225+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b40ee35b-8ba6-4159-bc5a-f8c47135bc85", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.42, "x": 0.04, "y": 0.54 }, "kind": "chart", "text": "Number of newly started clinical trials in U.S. (2016-21)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.225+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e11bd5d4-791a-47fa-8803-0d712376ef52", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.4, "x": 0.55, "y": 0.28 }, "kind": "list", "text": "Key drivers: Favorable policy, Accelerated innovative drug development, Continuous R&D investment", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.225+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9245a129-739d-4459-89ca-57e24b3c038a", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "CAGR: 29%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:58+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-09ee9369c7ef", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.04, "y": 0.88 }, "kind": "source-note", "text": "Note: *Only including phase 1 to phase 3 trials, while excluding BE and TCM trials, phase 4 trials and IITs. Source: DXY, Trialtrove, L.E.K. research and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.225+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3c7b6f2a-74ab-4468-9236-9f6ff04d84d5", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "China clinical trial has experienced rapid growth over the past five years, driven by favorable policy, accelerated innovative drug developed, and continuous R&D investment", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.225+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4c078b04-ff60-407b-aa0d-dc872000e1fd", "parentComponentId": null } ], "metrics": [ { "metricRaw": "CAGR", "numberRaw": "29%", "numberKind": "percent", "actionTitle": "China clinical trial has experienced rapid growth over the past five years, driven by favorable policy, accelerated innovative drug developed, and continuous R&D investment", "calloutText": "China clinical trial has experienced rapid growth over the past five years, driven by favorable policy, accelerated innovative drug developed, and continuous R&D investment.", "numberScale": null, "numberValue": 29, "metricFamily": "growth_rate", "numberCurrency": null } ], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "88d8805a-9b08-431b-8523-9594c15adf24", "evidence": "chart/bar-vertical: Number of newly started clinical trials in China (2016-21)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:15:57.190951+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "d87fad6b-0c9b-45b6-bf4c-46a182e83faa", "evidence": "list/bullet: Key drivers: Favorable policy, Accelerated innovative drug development, Continuous R&D investment", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:15:57.151545+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 11, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 6, "name": "Problem & Complication", "beatId": "2e308d53-f564-4d1b-a207-755a279e3246", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Problem & Complication", "slug": "consultants-gambit-problem-complication", "status": "active", "canonId": "019dd9b8-064a-777f-a374-e9a8c43dedd4", "version": 1, "description": null }, "evidence": "The report discusses the challenges facing China's clinical development, including COVID-19 uncertainties and funding challenges.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 8, "type": "analysis", "title": "The slide uses a honeycomb layout to group regulatory initiatives. Color coding indicates the nature of the policy (R&D, Registration, Pricing/Market Access, Co", "function": "summarize", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 6, "textChars": 879, "nDataPoints": 0, "notes": "The slide uses a honeycomb layout to group regulatory initiatives. Color coding indicates the nature of the policy (R&D, Registration, Pricing/Market Access, Commercialization).", "elementsJson": [ "headline_text", "process_diagram", "icon_grid", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:37.987+00", "seconds": 2.803, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/8", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-8", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Over the past 5 years, Chinese government has initiated a series of policies for healthcare industry, mostly positive for innovative drugs", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:59+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-ad01b9821252", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.8, "x": 0.05, "y": 0.3 }, "kind": "diagram", "text": "Honeycomb diagram of regulatory initiatives", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": "other", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.987+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fead2cae-afca-4573-b59a-c7cd9bcdd1ae", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.82, "y": 0.2 }, "kind": "legend", "text": "Positive for innovative drugs, R&D related, Registration related, Pricing and market access related, Commercialization related", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.987+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d07ed27d-a854-456b-87ae-c10618e8fb64", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.03, "y": 0.21 }, "kind": "paragraph", "text": "Key regulatory initiatives impacting China pharmaceutical market* (2017-2021)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.987+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cadbc954-b7bf-4153-927b-254dda097bb8", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.03, "y": 0.88 }, "kind": "source-note", "text": "Note: *CTA: Clinical Trial Application; DIP: Diagnosis-Intervention Packet; DRG: Diagnosis Related Groups; GBA: The Greater Bay Area; ICH: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; NRDL: National Reimbursement Drug List; RWE: Real World Evidence. Source: NMPA, L.E.K. analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.987+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8f8c1a53-6016-413f-8f30-4d9c1a76b158", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Favorable policy: Over the past 5 years, Chinese government has initiated a series of policies for healthcare industry, mostly positive for innovative drugs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:37.987+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bc3a7d5d-2ba3-4195-919d-127bffb07d8a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 11, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 6, "name": "Problem & Complication", "beatId": "2e308d53-f564-4d1b-a207-755a279e3246", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Problem & Complication", "slug": "consultants-gambit-problem-complication", "status": "active", "canonId": "019dd9b8-064a-777f-a374-e9a8c43dedd4", "version": 1, "description": null }, "evidence": "The report discusses the challenges facing China's clinical development, including COVID-19 uncertainties and funding challenges.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 9, "type": "analysis", "title": "The slide uses stacked bar charts to show the composition of clinical trials by phase (I, II, III) for China and the US.", "function": "analyze_data", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 91, "componentCount": 10, "textChars": 1494, "nDataPoints": 18, "notes": "The slide uses stacked bar charts to show the composition of clinical trials by phase (I, II, III) for China and the US.", "elementsJson": [ "headline_text", "bar_chart_stacked", "bullet_list", "quote_block", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:39.303+00", "seconds": 3.581, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/9", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-9", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Strong growth of trial number in China has been fueled particularly by development of innovative drugs", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:59+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-880132633b8c", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.45, "x": 0.04, "y": 0.215 }, "kind": "chart", "text": "Number of newly started clinical trials by trial phase (China)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.303+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18a95d4e-f166-4755-a49c-55b8911d39fd", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.45, "x": 0.04, "y": 0.53 }, "kind": "chart", "text": "Number of newly started clinical trials by trial phase (US)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.303+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "674a7290-5ee1-4891-96eb-c058e17c4ae0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.03, "y": 0.88 }, "kind": "disclaimer", "text": "Note: *Only including phase 1 to phase 3 trials, while excluding BE and TCM trials, phase 4 trials and IITs. Source: DXY, CPEA (China Pharmaceutical Enterprises Association), L.E.K. research and analysis", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.303+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "09805e4e-c614-411d-9962-228e221c0885", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.53, "y": 0.3 }, "kind": "list", "text": "Strong growth of trial number in China has been fueled particularly by development of innovative drugs. Faster early-stage trial growth, i.e., phase I and II trials, has been witnessed from 2016 to 2021, with a 29% and 47% CAGR respectively.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.303+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "961d23dc-caf0-456e-ac22-2a45cf148428", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.45, "x": 0.53, "y": 0.53 }, "kind": "list", "text": "China has also become a leader of clinical development in certain areas of innovation globally, such as CAR-T and ADC", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.303+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ad35b55c-57a6-4e3b-ac07-325dd7da6c32", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "CAGR: 47%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:59+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-90770b22936d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.53, "y": 0.62 }, "kind": "quote", "text": "From the view of absolute trial number and growth, China is leading in areas like CAR-T, large molecule, BsAb and ADC globally, with local companies and talents nurtured with the support of policy makers, PEVCs, MNCs, etc. in the past 10 years", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.303+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4adabfcc-0cc9-42a3-baa4-567cf71b5eb6", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "\"... From the view of absolute trial number and growth, China is leading in areas like CAR-T, large molecule, BsAb and ADC globally, with local companies and talents nurtured with the support of policy makers, PEVCs, MNCs, etc. in the past 10 years ...\" - Medical Lead, a Chinese biotech, Nov. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:59+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-8e00dc66c7ca", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.95, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Accelerated innovative drug developed: China has witnessed a strong growth of early-phase clinical trials, quickly catching up with global innovation capability", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.303+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e866f9a6-f193-46bd-b066-64951e4465f9", "parentComponentId": null } ], "metrics": [ { "metricRaw": "CAGR", "numberRaw": "47%", "numberKind": "percent", "actionTitle": "Accelerated innovative drug developed: China has witnessed a strong growth of early-phase clinical trials, quickly catching up with global innovation capability", "calloutText": "Strong growth of trial number in China has been fueled particularly by development of innovative drugs", "numberScale": null, "numberValue": 47, "metricFamily": "growth_rate", "numberCurrency": null } ], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "14957684-3318-45b3-a029-fb08dcbf04c2", "evidence": "chart/bar-stacked: Number of newly started clinical trials by trial phase (China)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 03:15:57.351196+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "51baa571-7733-403a-95a5-92375c7d2dd3", "evidence": "list/bullet: Strong growth of trial number in China has been fueled particularly by development of innovative drugs.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:15:57.311279+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 11, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 6, "name": "Problem & Complication", "beatId": "2e308d53-f564-4d1b-a207-755a279e3246", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Problem & Complication", "slug": "consultants-gambit-problem-complication", "status": "active", "canonId": "019dd9b8-064a-777f-a374-e9a8c43dedd4", "version": 1, "description": null }, "evidence": "The report discusses the challenges facing China's clinical development, including COVID-19 uncertainties and funding challenges.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 10, "type": "analysis", "title": "Data refers to enterprises above designated annual revenue size (>20M RMB). Exchange rate 6.25 used.", "function": "analyze_data", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 74, "componentCount": 7, "textChars": 1209, "nDataPoints": 12, "notes": "Data refers to enterprises above designated annual revenue size (>20M RMB). Exchange rate 6.25 used.", "elementsJson": [ "headline_text", "bar_chart_vertical", "bullet_list" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:42.82+00", "seconds": 6.964, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/10", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-10", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Under encouraging policy, Chinese pharmas are sparing more efforts on drug development, supported by rising R&D expenditure with a 14% CAGR from 2016-2021, higher than that in U.S.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:58+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-6d5b95c3f5ee", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.45, "x": 0.03, "y": 0.215 }, "kind": "chart", "text": "China pharma R&D expenditure (2016-21)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d4acddb-aa23-44d1-8ee3-f7282985b429", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.45, "x": 0.03, "y": 0.53 }, "kind": "chart", "text": "U.S. pharma R&D expenditure (2016-21)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "948c3022-1473-49e4-8b98-dbadb92041f1", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.45, "x": 0.52, "y": 0.33 }, "kind": "list", "text": "Under encouraging policy, Chinese pharmas are sparing more efforts on drug development, supported by rising R&D expenditure with a 14% CAGR from 2016-2021, higher than that in U.S. PE/VC investment, reaching 20 billions of USD in 2021 with a 50% CAGR from 2016 to 2021, has largely supported drug R&D in China. Continuous R&D investment has resulted in the steady growth of patents held by Chinese pharmas, which reached 57 thousand in 2020 with a ~11% CAGR from 2016 to 2020", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18a2b645-d80c-4664-98d3-d219452d47b9", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "R&D expenditure CAGR: 14%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:58+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-711c9765172f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.03, "y": 0.88 }, "kind": "source-note", "text": "Note: *Data refer to enterprises above designated annual revenue size, usually > 20 millions of RMB; RMB-USD exchange rate applied is 6.25 referring to Dec. 31, 2021. Source: National Bureau of Statistics, IQVIA, The Pharmaceutical Research and Manufacturers of America, L.E.K. research and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54ef51c6-f050-4b6f-bdbf-e10af9d9c702", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.94, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "Continuous R&D investment: Robust pharma R&D expenditure and patent number growth have sustained the underlying growth of China clinical trials in the past", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.82+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7ab17b2c-6272-4b80-9d9d-034d91e4b66b", "parentComponentId": null } ], "metrics": [ { "metricRaw": "R&D expenditure CAGR", "numberRaw": "14%", "numberKind": "percent", "actionTitle": "Continuous R&D investment: Robust pharma R&D expenditure and patent number growth have sustained the underlying growth of China clinical trials in the past", "calloutText": "Under encouraging policy, Chinese pharmas are sparing more efforts on drug development, supported by rising R&D expenditure with a 14% CAGR from 2016-2021, higher than that in U.S.", "numberScale": null, "numberValue": 14, "metricFamily": "growth_rate", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [ { "to": 11, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 6, "name": "Problem & Complication", "beatId": "2e308d53-f564-4d1b-a207-755a279e3246", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Problem & Complication", "slug": "consultants-gambit-problem-complication", "status": "active", "canonId": "019dd9b8-064a-777f-a374-e9a8c43dedd4", "version": 1, "description": null }, "evidence": "The report discusses the challenges facing China's clinical development, including COVID-19 uncertainties and funding challenges.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 11, "type": "analysis", "function": "diagnose", "rawType": "pain_points", "block": null, "metadata": { "slideType": "pain_points", "slideTypeCanon": { "name": "Pain points", "slug": "pain_points", "status": "active", "canonId": "019de52d-08a0-761d-a14f-1dbc5e447381", "version": 1, "description": null }, "function": "diagnose", "functionCanon": { "name": "Diagnose", "slug": "diagnose", "status": "active", "canonId": "019de52d-1657-7223-acc5-7437d878c850", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 7, "textChars": 831, "nDataPoints": 0, "notes": null, "elementsJson": [ "headline_text", "icon_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:43.822+00", "seconds": 7.785, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/11", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-11", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.14, "w": 0.925, "x": 0.037, "y": 0.27 }, "kind": "list", "text": "COVID-19 uncertainties: Difficulties in patient recruitment; Potential trial progress delay due to regional lockdowns", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49c932ed-4b62-453a-8fa2-b60bf7d344d4", "parentComponentId": null }, { "bbox": { "h": 0.14, "w": 0.925, "x": 0.037, "y": 0.63 }, "kind": "list", "text": "Homogeneous competition: Homogeneous competition of Chinese pharmaceutical companies, especially around popular targets such as PD-1/L1", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6e5b3d91-203f-4226-8e57-3b8434dfc198", "parentComponentId": null }, { "bbox": { "h": 0.14, "w": 0.925, "x": 0.037, "y": 0.81 }, "kind": "list", "text": "Regulatory pressure: Stringent R&D requirements such as potential head-to-head trial for oncology drug; Price and profit cutdown brought by VBP and NRDL negotiation", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "707a3b6c-c8ee-4555-bc15-8b307f90df39", "parentComponentId": null }, { "bbox": { "h": 0.14, "w": 0.925, "x": 0.037, "y": 0.45 }, "kind": "list", "text": "Funding challenges: Hard to obtain funding as financial investors become more cautious due to economy slowdown and price pressure in Chinese stock markets", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "883c3bd7-b473-4260-b5fa-2ddd3eef01fb", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.037, "y": 0.9 }, "kind": "source-note", "text": "Source: DXY, Trialtrove, L.E.K. interviews and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0972b177-01ea-4429-bf65-b9d91a23de25", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.925, "x": 0.037, "y": 0.06 }, "kind": "title", "text": "Meanwhile, headwinds facing China clinical development are also significant: COVID-19 uncertainties, funding challenges, homogeneous competition and regulatory pressure", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "927ddb73-64da-4570-b588-ce342597de2b", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.037, "y": 0.21 }, "kind": "title", "text": "Challenges of China pharmaceutical R&D", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.822+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f3c5fc58-87f7-45a9-8feb-70315f234f6d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "436dd1af-d7d9-47b6-a8dd-021cc1911876", "evidence": "list/bullet: Regulatory pressure: Stringent R&D requirements such as potential head-to-head trial for oncology drug; Price and profit cutdown brought by VBP and NRDL negotiation", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-16 21:14:35.553184+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 11, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 6, "name": "Problem & Complication", "beatId": "2e308d53-f564-4d1b-a207-755a279e3246", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Problem & Complication", "slug": "consultants-gambit-problem-complication", "status": "active", "canonId": "019dd9b8-064a-777f-a374-e9a8c43dedd4", "version": 1, "description": null }, "evidence": "The report discusses the challenges facing China's clinical development, including COVID-19 uncertainties and funding challenges.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f", "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.", "position": 0, "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:14:56.308784+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "setup", "title": "The slide combines quantitative survey data (N=101) with qualitative expert quotes to contextualize the market sentiment.", "function": "summarize", "rawType": "testimonial", "block": null, "metadata": { "slideType": "testimonial", "slideTypeCanon": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52d-0a2d-7782-8a48-7e84df92cc97", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 8, "textChars": 1041, "nDataPoints": 4, "notes": "The slide combines quantitative survey data (N=101) with qualitative expert quotes to contextualize the market sentiment.", "elementsJson": [ "bar_chart_100pct", "quote_block", "photo" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:39.099+00", "seconds": 2.795, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/12", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-12", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "However, ~60% of respondents still show a positive attitude towards future trial number growth, with confidence that China clinical development is pivoting to a high-quality growth", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:02+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-5b48b69214d6", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.2, "x": 0.05, "y": 0.3 }, "kind": "chart", "text": "Stacked bar chart showing 5%, 36%, 34%, 26% distribution", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e8cfe2ef-4394-489a-bbcd-7a13fd7e7d9a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.85 }, "kind": "disclaimer", "text": "Note: *Survey question: In the next 5 years (2022-27), what's your view on China clinical trial growth rate compared with historical growth (2016-21)?", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cf9c0d75-8b36-4990-a726-1dffc7ac75b2", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Percent of respondents: 60%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:02+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-61c46df7decf", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.5, "x": 0.45, "y": 0.3 }, "kind": "quote", "text": "Market feedback: quotes from CEO, R&D Lead, and CEO regarding trial growth and innovation.", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "71dff259-90ce-4200-8bcd-d27196891792", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "The industry is going to keep growing fast because its foundation is solid. We are ready to apply theories into applications among various TAs, our population provides a great base for research, and pioneers have validated the business model for new entrants... - CEO, a Chinese biotech, Oct. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:02+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-5d9677406766", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "However, ~60% of respondents still show a positive attitude towards future trial number growth, with confidence that China clinical development is pivoting to a high-quality growth", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "80429f63-34cf-4ae5-9f9f-77a12d30f3e9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.05, "y": 0.2 }, "kind": "title", "text": "Perspectives on clinical trial number growth rate in 2022-27*", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f922de5c-240d-469d-b4e7-b6b6915ba5a5", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Percent of respondents", "numberRaw": "60%", "numberKind": "percent", "actionTitle": "However, ~60% of respondents still show a positive attitude towards future trial number growth, with confidence that China clinical development is pivoting to a high-quality growth", "calloutText": "However, ~60% of respondents still show a positive attitude towards future trial number growth, with confidence that China clinical development is pivoting to a high-quality growth", "numberScale": null, "numberValue": 60, "metricFamily": "survey_sentiment", "numberCurrency": null } ], "tools": [], "frameworks": [ { "matchId": "1f4e6984-0a6f-46f8-9e35-b21b5bd44395", "evidence": "Use of direct quotes from industry experts to support the quantitative data.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 19:22:39.099+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "testimonial" } ], "arcBeats": [ { "to": 20, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 12, "name": "Solution & Approach", "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Solution & Approach", "slug": "consultants-gambit-solution-approach", "status": "active", "canonId": "019dd9b8-071c-7161-9184-580fdac7a4f9", "version": 1, "description": null }, "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f", "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.", "position": 0, "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:14:56.308784+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "setup", "function": "summarize", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "sparse", "densityScore": 8, "componentCount": 2, "textChars": 178, "nDataPoints": 0, "notes": null, "elementsJson": [ "bullet_list" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:38.773+00", "seconds": 2.427, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/13", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-13", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.45, "x": 0.038, "y": 0.218 }, "kind": "list", "text": "Context of clinical trial development in China\nFuture strategic trends of clinical trial development in China\nNext step questions\nResources and references\nAbout the authors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:38.773+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a1bfad5-c4b3-4dbe-ace3-8c9f3a061fe3", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.085, "x": 0.038, "y": 0.143 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:38.773+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e231f8d8-f35b-455e-a768-da1da8c39331", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 12, "name": "Solution & Approach", "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Solution & Approach", "slug": "consultants-gambit-solution-approach", "status": "active", "canonId": "019dd9b8-071c-7161-9184-580fdac7a4f9", "version": 1, "description": null }, "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f", "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.", "position": 0, "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:14:56.308784+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "analysis", "function": "summarize", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "sparse", "densityScore": 22, "componentCount": 3, "textChars": 407, "nDataPoints": 0, "notes": null, "elementsJson": [ "headline_text", "numbered_list", "icon_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:39.618+00", "seconds": 3.151, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/14", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-14", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.35, "x": 0.06, "y": 0.32 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.618+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e99cf555-669c-4618-8f80-89533eb58c12", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.45, "x": 0.42, "y": 0.25 }, "kind": "list", "text": "01 Development of More Innovative and Differentiated Therapies\n02 Increasing Focus of More Commercially Attractive Development Areas\n03 Adoption of Smarter Clinical Trial Tools\n04 A Two-way Pursuit: Globalization of Chinese Biopharma & Evolution of MNC China R&D strategy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.618+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f9c34daf-3449-4f62-bbac-3d61a3b0cd31", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.92, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "We anticipate 4 strategic trends of clinical trial development under the transformation from extensive growth to quality growth in China", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.618+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c723e870-9931-4051-b74b-a1c9d697dfcb", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1e6eb92b-34c4-4f5a-af5c-47d6ed881471", "evidence": "list/numbered: 01 Development of More Innovative and Differentiated Therapies", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-16 21:14:35.689086+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 12, "name": "Solution & Approach", "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Solution & Approach", "slug": "consultants-gambit-solution-approach", "status": "active", "canonId": "019dd9b8-071c-7161-9184-580fdac7a4f9", "version": 1, "description": null }, "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f", "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.", "position": 0, "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:14:56.308784+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "setup", "function": "front_matter", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 20, "componentCount": 2, "textChars": 438, "nDataPoints": 0, "notes": null, "elementsJson": [ "bullet_list" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:55.803+00", "seconds": 19.276, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/15", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-15", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.52, "w": 0.61, "x": 0.038, "y": 0.215 }, "kind": "list", "text": "Context of clinical trial development in China\nFuture strategic trends of clinical trial development in China\nDevelopment of More Innovative and Differentiated Therapies\nIncreasing Focus of More Commercially Attractive Development Areas\nAdoption of Smarter Clinical Trial Tools\nA Two-way Pursuit: Globalization of Chinese Biopharma & Evolution of MNC China R&D strategy\nNext step questions\nResources and references\nAbout the authors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:55.803+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "58998647-8006-45d4-8b8e-de63d1f36637", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.085, "x": 0.038, "y": 0.145 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:55.803+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e643a91b-670f-450e-be28-5fd52f297507", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 12, "name": "Solution & Approach", "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Solution & Approach", "slug": "consultants-gambit-solution-approach", "status": "active", "canonId": "019dd9b8-071c-7161-9184-580fdac7a4f9", "version": 1, "description": null }, "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f", "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.", "position": 0, "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:14:56.308784+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 16, "type": "analysis", "title": "The chart uses a broken y-axis to accommodate the large number of companies in the 1-5 project range.", "function": "analyze_data", "rawType": "market_landscape", "block": null, "metadata": { "slideType": "market_landscape", "slideTypeCanon": { "name": "Market landscape", "slug": "market_landscape", "status": "active", "canonId": "019de52d-0b6d-75db-a946-9ac362e3afc2", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 6, "textChars": 546, "nDataPoints": 28, "notes": "The chart uses a broken y-axis to accommodate the large number of companies in the 1-5 project range.", "elementsJson": [ "headline_text", "bar_chart_stacked", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:45.103+00", "seconds": 8.565, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/16", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-16", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.675, "w": 0.928, "x": 0.036, "y": 0.215 }, "kind": "chart", "text": "Distribution of Chinese innovative pharmas by number of class 1 innovative projects* (823 companies in total) (2021)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.103+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "044804ea-9c97-45a6-b6d9-a7718ad6a1d6", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.41, "x": 0.036, "y": 0.888 }, "kind": "disclaimer", "text": "Note: * Include domestic and global class-1 new-drug (一类创新药) pipeline or marketed products. Source: DXY, Qichacha, L.E.K. analysis", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.103+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d39e15e9-8960-479a-b8f7-b391ee354c08", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.156, "x": 0.788, "y": 0.325 }, "kind": "legend", "text": "With foreign capital; With Chinese-only capital", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.103+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "01429d03-cdbf-4207-811b-56dbb57957fc", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Number of companies: 823", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:58+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-543d0c93df6f", "parentComponentId": null }, { "bbox": { "h": 0.041, "w": 0.928, "x": 0.036, "y": 0.061 }, "kind": "title", "text": "Chinese pharma companies have surely made some progresses in innovation during the past few years, among which over 800 companies already have Class 1 innovative projects", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.103+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6c2f288d-58c0-48b5-a7c2-9ebd1b91e5b6", "parentComponentId": null }, { "bbox": { "h": 0.016, "w": 0.378, "x": 0.036, "y": 0.033 }, "kind": "title", "text": "Development of More Innovative and Differentiated Therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.103+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b3307573-e4c8-487a-962d-022924ac9ed2", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Number of companies", "numberRaw": "823", "numberKind": "plain", "actionTitle": "Chinese pharma companies have surely made some progresses in innovation during the past few years, among which over 800 companies already have Class 1 innovative projects", "calloutText": null, "numberScale": null, "numberValue": 823, "metricFamily": "survey_sentiment", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 12, "name": "Solution & Approach", "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Solution & Approach", "slug": "consultants-gambit-solution-approach", "status": "active", "canonId": "019dd9b8-071c-7161-9184-580fdac7a4f9", "version": 1, "description": null }, "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f", "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.", "position": 0, "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:14:56.308784+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 17, "type": "analysis", "title": "The chart displays 4 categories of FDA designations with stacked segments representing product types.", "function": "analyze_data", "rawType": "data_table", "block": null, "metadata": { "slideType": "data_table", "slideTypeCanon": { "name": "Data table", "slug": "data_table", "status": "active", "canonId": "019de52d-0bbd-71b9-9918-417f904abbf8", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 70, "componentCount": 7, "textChars": 910, "nDataPoints": 12, "notes": "The chart displays 4 categories of FDA designations with stacked segments representing product types.", "elementsJson": [ "headline_text", "bar_chart_stacked", "bullet_list", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:39.848+00", "seconds": 3.126, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/17", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-17", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Around 30% of Chinese biopharmas' products with FDA designation are self-claimed first/best-in-class", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:58+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbb-b976b9a0724f", "parentComponentId": null }, { "bbox": { "h": 0.52, "w": 0.55, "x": 0.038, "y": 0.32 }, "kind": "chart", "text": "Stacked bar chart showing product counts by designation type", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.848+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8a422df9-cc38-42de-a735-eb6bcbbefb66", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.28, "x": 0.67, "y": 0.4 }, "kind": "list", "text": "FDA has developed four programs to facilitate and expedite the development of new drugs. Around 30% of Chinese biopharmas' products with FDA designation are self-claimed first/best-in-class.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.848+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1e82f048-fab6-4fc0-91e0-0ab83abb6806", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Number of products: 21", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:17:58+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbb-bd97297becc5", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.85, "x": 0.038, "y": 0.86 }, "kind": "source-note", "text": "Note: *FDA designs four special designations to facilitate and expedite the review of drugs to get important new drugs to the patient earlier; **Based on notes in Pharmaprojects for each trial, as FDA has not disclosed such data. Source: U.S. FDA, Pharmaprojects, L.E.K. analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.848+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b3dee8f-2719-4602-ae3a-20a807f9a2b8", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.92, "x": 0.038, "y": 0.06 }, "kind": "title", "text": "Some innovative assets also managed to obtain FDA special designation through filling unmet needs on serious conditions or significant improvement on effectiveness", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.848+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "672a6fc7-d6fc-4e5f-a53e-07c29104f6e8", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.55, "x": 0.038, "y": 0.22 }, "kind": "title", "text": "Number of Chinese biopharmas' products with FDA special designation* (not exclusive**) (2017-21)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.848+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "96cfb22c-5fac-4033-bbd5-02a9b4bbf566", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Number of products", "numberRaw": "21", "numberKind": "plain", "actionTitle": "Some innovative assets also managed to obtain FDA special designation through filling unmet needs on serious conditions or significant improvement on effectiveness", "calloutText": "Around 30% of Chinese biopharmas' products with FDA designation are self-claimed first/best-in-class", "numberScale": null, "numberValue": 21, "metricFamily": "volume_count", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 12, "name": "Solution & Approach", "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Solution & Approach", "slug": "consultants-gambit-solution-approach", "status": "active", "canonId": "019dd9b8-071c-7161-9184-580fdac7a4f9", "version": 1, "description": null }, "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f", "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.", "position": 0, "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:14:56.308784+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 18, "type": "analysis", "title": "The slide highlights the 'me-too' drug development problem in China.", "function": "frame_problem", "rawType": "market_landscape", "block": null, "metadata": { "slideType": "market_landscape", "slideTypeCanon": { "name": "Market landscape", "slug": "market_landscape", "status": "active", "canonId": "019de52d-0b6d-75db-a946-9ac362e3afc2", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 86, "componentCount": 9, "textChars": 1233, "nDataPoints": 10, "notes": "The slide highlights the 'me-too' drug development problem in China.", "elementsJson": [ "headline_text", "bar_chart_vertical", "quote_block" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:39.575+00", "seconds": 2.854, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/18", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-18", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Chasing heated targets without differentiation is unsustainable.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:00+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-f309668dd1b6", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.92, "x": 0.038, "y": 0.22 }, "kind": "chart", "text": "Accumulated number of molecules in the newly started trials of Top 10 targets (2016-21)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.575+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "31aba4b7-59d3-4792-86b1-a174febf04b2", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Number of molecules: 57", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:00+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-f8416e661783", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.92, "x": 0.04, "y": 0.65 }, "kind": "quote", "text": "Chasing heated targets without differentiation is unsustainable. Currently, nearly 100 companies in China have entered PD-1 area, however their efficacy and safety profile are similar, which may lead to a situation like generic drugs...", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.575+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4d223bc4-c62a-479a-b5f8-61758cd08c67", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.92, "x": 0.04, "y": 0.78 }, "kind": "quote", "text": "Take monoclonal antibodies as example, 60% of them in China are focused on 5 mechanisms while globally, it is quite diverse with multiple mechanisms. Policy makers have also been aware of the homogeneous competition and are pushing for the adoption of head-to-head comparison with the best SoC...", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.575+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eeb40f4b-16e9-413d-97a2-eee104188e3b", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "Chasing heated targets without differentiation is unsustainable. Currently, nearly 100 companies in China have entered PD-1 area, however their efficacy and safety profile are similar, which may lead to a situation like generic drugs... - Medical Lead, a Chinese biotech, Sept. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:00+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-f5c012997275", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.2, "x": 0.038, "y": 0.91 }, "kind": "source-note", "text": "Source: DXY, L.E.K. research and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.575+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c4be558d-de78-483f-a6e3-232d9f620092", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.92, "x": 0.038, "y": 0.06 }, "kind": "title", "text": "However, past innovation mainly concentrated around heated targets, leading to the rising concern of homogeneous competition for pharmas in China", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.575+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dadde704-24a0-4a02-aac5-439df3986f05", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.38, "x": 0.038, "y": 0.03 }, "kind": "title", "text": "Development of More Innovative and Differentiated Therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.575+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c0afdbbd-3d68-4a4b-8f59-c1f84c7c13f4", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Number of molecules", "numberRaw": "57", "numberKind": "plain", "actionTitle": "However, past innovation mainly concentrated around heated targets, leading to the rising concern of homogeneous competition for pharmas in China", "calloutText": "Chasing heated targets without differentiation is unsustainable.", "numberScale": null, "numberValue": 57, "metricFamily": "volume_count", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 12, "name": "Solution & Approach", "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Solution & Approach", "slug": "consultants-gambit-solution-approach", "status": "active", "canonId": "019dd9b8-071c-7161-9184-580fdac7a4f9", "version": 1, "description": null }, "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f", "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.", "position": 0, "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:14:56.308784+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 19, "type": "analysis", "title": "The slide uses a dual-column layout to contrast market drivers (left) with specific regulatory examples (right).", "function": "establish_context", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 85, "componentCount": 11, "textChars": 1412, "nDataPoints": 0, "notes": "The slide uses a dual-column layout to contrast market drivers (left) with specific regulatory examples (right).", "elementsJson": [ "headline_text", "bullet_list", "callout_box", "footnote", "icon_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:40.5+00", "seconds": 3.586, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/19", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-19", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Stringent regulations and pharmas' commercial considerations are driving the development of truly innovative and differentiated therapies in China.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:00+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbc-c9f29040296c", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.28, "x": 0.11, "y": 0.73 }, "kind": "list", "text": "CDE is raising the technical requirements for clinical development", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0bc2299a-a632-4e5a-85aa-7ba3951c7f2d", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.45, "x": 0.51, "y": 0.41 }, "kind": "list", "text": "If the drug fails to achieve desired effect in early clinical trials... decisions should be made in time to stop patient enrollment or terminate R&D of the drug. Drugs with uncertain safety / effectiveness or suboptimal drugs should not be selected as control.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "42c4c6ac-5380-4fd2-a50f-edfb651803e9", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.45, "x": 0.51, "y": 0.73 }, "kind": "list", "text": "Unless a new mechanism is created through BsAb structure, otherwise, whether it is necessary for BsAb development should be considered carefully if other target already has druggability. If the BsAb targets include the mono therapy, it is required to include mono therapy from SoC** for the control group", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d3b007a-2afa-4aa3-a241-b5627b58fb5d", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.28, "x": 0.11, "y": 0.31 }, "kind": "list", "text": "Financial return is limited for drugs with fierce homogenous competition", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a098c86c-83dd-4226-b3af-f404b2ff337f", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.28, "x": 0.11, "y": 0.52 }, "kind": "list", "text": "More difficult for homogenous drug asset to obtain financial funding", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8bb36d4-7bcf-44a5-ab00-0e9bfe8c3e52", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.45, "x": 0.51, "y": 0.27 }, "kind": "paragraph", "text": "Guiding Principles for Clinical Value-Oriented Clinical Development of Oncology Drugs", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2c00df9d-4f44-4097-b87e-925b99232d09", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.45, "x": 0.51, "y": 0.59 }, "kind": "paragraph", "text": "Guiding Principles for Clinical Development of BsAb* Oncology Drugs (Draft for Comments)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f41975a3-5725-4054-b5c5-c6c5c7d38fb3", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.28, "x": 0.038, "y": 0.89 }, "kind": "source-note", "text": "Note: *BsAb: Bispecific Antibodies; **SoC: Standard of Care. Source: CDE, NMPA, Ping'An, L.E.K. research and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "23032ddd-5009-4956-901d-9de4a291f1f2", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.92, "x": 0.038, "y": 0.06 }, "kind": "title", "text": "Stringent regulations and pharmas' commercial considerations are driving the development of truly innovative and differentiated therapies in China", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6a6c5eef-7258-4c1f-ad77-9a92a74bcbfd", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.38, "x": 0.038, "y": 0.03 }, "kind": "title", "text": "Development of More Innovative and Differentiated Therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.5+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "473a4a72-4cf2-4f55-8b0c-78724039799a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 12, "name": "Solution & Approach", "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Solution & Approach", "slug": "consultants-gambit-solution-approach", "status": "active", "canonId": "019dd9b8-071c-7161-9184-580fdac7a4f9", "version": 1, "description": null }, "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f", "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.", "position": 0, "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:14:56.308784+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 20, "type": "analysis", "title": "The slide uses a stacked bar chart to show survey responses and a callout box for qualitative expert feedback.", "function": "summarize", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 8, "textChars": 1017, "nDataPoints": 3, "notes": "The slide uses a stacked bar chart to show survey responses and a callout box for qualitative expert feedback.", "elementsJson": [ "headline_text", "bar_chart_stacked", "quote_block", "footnote", "photo" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:42.726+00", "seconds": 5.545, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/20", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-20", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "In order to survive, they must find a differentiated path; for instance, smartly leverage its own capability or be a pilot in a niche TA.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:00+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbd-60cae631d769", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.35, "x": 0.04, "y": 0.21 }, "kind": "chart", "text": "Perspectives on the future trend of homogeneous competition in China* (N=101)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.726+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b9d8e0c1-b85e-4e41-b752-d74a95ad7f79", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.85 }, "kind": "disclaimer", "text": "Note: *Survey questions: China in-trial products are more and more homogeneous as many in-trial / in-market products are of same target and mechanism (e.g., PD-1), which brings significant challenges to future commercialization.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.726+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "26ca5db1-6d57-450b-96bc-25be1c473e93", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Percent of respondents: 70%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:00+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbd-68cff110ce9a", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.44, "x": 0.52, "y": 0.21 }, "kind": "quote", "text": "Market feedback", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.726+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "84dd8775-3702-4737-b307-393326f42622", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "In capital market, investors are beginning to realize that companies are mostly playing with repetitive technologies and lack of true innovation. In the future, investors tend not to invest in me-copy drugs, further cutting down the number of homogeneous trials. - CEO, a Chinese biopharma, Sept. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:00+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbd-66d4f7d8ee22", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.92, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "~70% of respondents also believe that homogeneous competition will relieve in next 5 years with company focus shifting to innovative, differentiated and China-specific drugs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.726+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5af0e4cc-3406-48ff-a2cf-45fe8ea13084", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.04, "y": 0.03 }, "kind": "title", "text": "Development of More Innovative and Differentiated Therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.726+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5069f6d8-4f89-4539-a173-f7b6cbb090a9", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Percent of respondents", "numberRaw": "70%", "numberKind": "percent", "actionTitle": "~70% of respondents also believe that homogeneous competition will relieve in next 5 years with company focus shifting to innovative, differentiated and China-specific drugs", "calloutText": "In order to survive, they must find a differentiated path; for instance, smartly leverage its own capability or be a pilot in a niche TA.", "numberScale": null, "numberValue": 70, "metricFamily": "survey_sentiment", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Consultant's Gambit", "slug": "consultants-gambit", "status": "active", "bestFor": "Business cases, project proposals, strategic recommendations", "canonId": "019dd956-5e0a-73c8-b305-81c38c959e9c", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Situation & Context -> Problem & Complication -> Solution & Approach -> Evidence & Proof -> Impact & Next Steps", "description": null, "familyLabel": null }, "from": 12, "name": "Solution & Approach", "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580", "matchId": "9371fc18-5f84-44eb-9b31-36e273975c86", "beatType": { "name": "Solution & Approach", "slug": "consultants-gambit-solution-approach", "status": "active", "canonId": "019dd9b8-071c-7161-9184-580fdac7a4f9", "version": 1, "description": null }, "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 20, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f", "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.", "position": 0, "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:14:56.308784+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "analysis", "title": "The slide uses stacked bar charts to show clinical trial phases over time, with CAGR annotations.", "function": "analyze_data", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 8, "textChars": 865, "nDataPoints": 12, "notes": "The slide uses stacked bar charts to show clinical trial phases over time, with CAGR annotations.", "elementsJson": [ "headline_text", "bar_chart_stacked", "quote_block", "photo" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:44.977+00", "seconds": 7.549, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/21", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-21", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "In the meantime, to tackle homogeneous competition, companies are focusing on a wide range of new modalities, such as BsAb, ADC and C>, which are expected to largely diversify the China landscape.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:05+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cc0-647be729ec54", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.5, "x": 0.03, "y": 0.21 }, "kind": "chart", "text": "Number of newly started clinical trials by modality (2018-21)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.977+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "420b2557-24e5-4dec-b3c8-263aeb409f50", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Number of newly started clinical trials: 124%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:05+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cc0-6ce30e87e8fa", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.4, "x": 0.55, "y": 0.21 }, "kind": "quote", "text": "Market feedback", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.977+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a9e0082a-c323-44e6-9cd9-019befea44e4", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "Our company starts to focus on cell and gene-oriented therapies which we think would be the major modalities in the future, as traditional modalities could only provide marginal benefit for patients ... - R&D Lead, a leading MNC pharma, Sept. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:05+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cc0-6a0addd133e0", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.03, "y": 0.9 }, "kind": "source-note", "text": "Source: DXY, L.E.K. interviews and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.977+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "70acc078-6ca0-48b6-8865-b38045e464b1", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.95, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "In the meantime, to tackle homogeneous competition, companies are focusing on a wide range of new modalities, such as BsAb, ADC and C>, which are expected to largely diversify the China landscape", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.977+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a589c923-1e84-4eb9-991f-3fd579d19d02", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.45, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Development of More Innovative and Differentiated Therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.977+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b771833c-53f8-43e7-94d3-fe6266a84aa8", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Number of newly started clinical trials", "numberRaw": "124%", "numberKind": "percent", "actionTitle": "In the meantime, to tackle homogeneous competition, companies are focusing on a wide range of new modalities, such as BsAb, ADC and C>, which are expected to largely diversify the China landscape", "calloutText": "In the meantime, to tackle homogeneous competition, companies are focusing on a wide range of new modalities, such as BsAb, ADC and C>, which are expected to largely diversify the China landscape.", "numberScale": null, "numberValue": 124, "metricFamily": "volume_count", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 22, "type": "evidence", "title": "The slide uses a three-row structure to map strategic pillars to real-world examples and qualitative expert validation.", "function": "illustrate_case", "rawType": "client_example", "block": null, "metadata": { "slideType": "client_example", "slideTypeCanon": { "name": "Client example", "slug": "client_example", "status": "active", "canonId": "019de52d-0c87-77cb-9867-613ae22e95ac", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "dense", "densityScore": 69, "componentCount": 8, "textChars": 854, "nDataPoints": 0, "notes": "The slide uses a three-row structure to map strategic pillars to real-world examples and qualitative expert validation.", "elementsJson": [ "headline_text", "icon_grid", "comparison_table", "quote_block", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:40.438+00", "seconds": 2.995, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/22", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-22", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.2, "x": 0.03, "y": 0.45 }, "kind": "list", "text": "Improve drug features (e.g., dosage form, route of administration, safety, indication expansion)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.438+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a0f4fa8a-2a52-4828-af1b-ba833ea73cf3", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.03, "y": 0.65 }, "kind": "list", "text": "Invest in cutting-edge technology platforms", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.438+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a6eeea54-1568-48b0-91c3-0ad35d56d792", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.03, "y": 0.25 }, "kind": "list", "text": "Discover new drug targets for TAs with unmet needs", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.438+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dd0751b3-0eae-4c76-b879-9504b2bfd2e6", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "Although developing new targets could be risky, it's worthy to take the risk because companies can avoid homogeneous competition and more importantly, it also boosts the progress of scientific development of the entire ecosystem ... - Science Lead, a Chinese CRO, May 2021", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:00+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbd-197bcd2ed2ac", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.03, "y": 0.88 }, "kind": "source-note", "text": "Note: *GCTTS: Giant Cell Tumor of Tendon Sheath (腱鞘巨细胞瘤) Source: Company websites, L.E.K. interviews and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.438+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c6fd42ae-8366-4dcd-9068-439c12c71fb3", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.7, "x": 0.25, "y": 0.2 }, "kind": "table", "text": "Business cases and Market feedback columns", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.438+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49751852-9060-4679-aa50-a0f5d143c777", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.9, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "In addition to new modalities, companies are also considering to tackle through discovering new targets, improving drug features and investing in cutting-edge technology platforms", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.438+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6b774914-e033-486e-9621-c5ce1724af14", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Development of More Innovative and Differentiated Therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.438+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b42ac7ec-6233-488a-b4f0-01f71ef8e50b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "af95a5d1-ae9f-4241-ae12-e251101256d8", "evidence": "The components list several potential solutions or areas of focus for drug development, such as discovering new targets, improving drug features, and investing in cutting-edge technology platforms, which indicates a problem statement or areas for improvement.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-16 21:14:26.1249+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 23, "type": "setup", "function": "front_matter", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 20, "componentCount": 2, "textChars": 438, "nDataPoints": 0, "notes": null, "elementsJson": [ "bullet_list" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:39.863+00", "seconds": 2.236, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/23", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-23", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.518, "w": 0.645, "x": 0.038, "y": 0.218 }, "kind": "list", "text": "Context of clinical trial development in China\nFuture strategic trends of clinical trial development in China\nDevelopment of More Innovative and Differentiated Therapies\nIncreasing Focus of More Commercially Attractive Development Areas\nAdoption of Smarter Clinical Trial Tools\nA Two-way Pursuit: Globalization of Chinese Biopharma & Evolution of MNC China R&D strategy\nNext step questions\nResources and references\nAbout the authors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.863+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8b72e1d6-7f60-4736-acef-cda4378de215", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.085, "x": 0.038, "y": 0.143 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:39.863+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee7ba948-6dc3-4d86-a119-1a2612181970", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 24, "type": "analysis", "title": "The chart shows a clear shift in clinical trial focus toward oncology, increasing from 30% in 2016 to 48% in 2022.", "function": "analyze_data", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 83, "componentCount": 8, "textChars": 1169, "nDataPoints": 49, "notes": "The chart shows a clear shift in clinical trial focus toward oncology, increasing from 30% in 2016 to 48% in 2022.", "elementsJson": [ "headline_text", "action_title", "bar_chart_stacked", "quote_block", "photo", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:40.858+00", "seconds": 2.734, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/24", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-24", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Oncology has become the most heated TA for clinical development in China over the past few years.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-75b60777bb4b", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.45, "x": 0.037, "y": 0.215 }, "kind": "chart", "text": "Number of newly started clinical trials by therapeutic area (2016-2022 Aug.)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart (100%)", "slug": "bar-stacked-100pct", "status": "active", "canonId": "019de52c-ff14-71b8-8d88-860f8d7da84b", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked-100pct", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.858+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ab76e5ef-5948-4274-ac37-6bb1009a8802", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.037, "y": 0.88 }, "kind": "disclaimer", "text": "Note: *Only including phase 1 to phase 3 trials, while excluding BE and TCM trials, phase 4 trials and IITs. Joint clinical trials between MNC and domestic companies are all counted as trials by Chinese company. Source: DXY, L.E.K. analysis", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.858+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6856b56c-fdc8-4cb0-9c26-6c80f1c57547", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Number of clinical trials: 48%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-7d871c1d7686", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.42, "x": 0.53, "y": 0.3 }, "kind": "quote", "text": "Previously, most players tended to develop products around mature targets and mechanism in oncology area such as PD-1... - Regulatory Lead, a Chinese biopharma, Oct.2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.858+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "97b60950-8560-4b0f-b95a-a3cbb9b94ae5", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.42, "x": 0.53, "y": 0.55 }, "kind": "quote", "text": "Oncology drives the past growth of China clinical trials... financial investors prefer to invest in risk-free innovation - President, a Chinese biopharma, Aug. 2021", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.858+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f1745d42-d472-41e8-93e3-d48616f71d8f", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "Oncology drives the past growth of China clinical trials, because on one hand, traditional pharmas attempt to quickly enter the promising biologics market, however, their 'generic-type' mindset cannot change overnight which has led to much 'fast-follow' - President, a Chinese biopharma, Aug. 2021", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-7beca2a22488", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.85, "x": 0.037, "y": 0.103 }, "kind": "title", "text": "Oncology has become the most heated TA for clinical development in China over the past few years", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.858+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "88b2d076-3e4c-4223-a8e9-df7f9c5787ed", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Number of clinical trials", "numberRaw": "48%", "numberKind": "percent", "actionTitle": "Oncology has become the most heated TA for clinical development in China over the past few years", "calloutText": "Oncology has become the most heated TA for clinical development in China over the past few years.", "numberScale": null, "numberValue": 48, "metricFamily": "volume_count", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 25, "type": "analysis", "title": "Uses a 'Past vs Future' transformation framework to illustrate strategic shift.", "function": "summarize", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 85, "componentCount": 10, "textChars": 1871, "nDataPoints": 0, "notes": "Uses a 'Past vs Future' transformation framework to illustrate strategic shift.", "elementsJson": [ "headline_text", "bullet_list", "process_diagram", "quote_block", "icon_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:41.923+00", "seconds": 3.782, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/25", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-25", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "With more innovative products being launched, market focus has shifted from previous “quick and successful launch” to “commercially attractive” as it directly decides a product’s ultimate success under increasingly homogeneous competition.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:01+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbd-8446c30bb50f", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.36, "x": 0.61, "y": 0.31 }, "kind": "list", "text": "With more innovative products being launched, market focus has shifted from previous “quick and successful launch” to “commercially attractive” as it directly decides a product’s ultimate success under increasingly homogeneous competition", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72ae483b-e75a-4fc4-a942-e2e927a15014", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.36, "x": 0.61, "y": 0.51 }, "kind": "list", "text": "More importantly, commercially attractive products better ensure company’s continuous future development: Sustainable fund for future innovative research; Strong valuation to attract future external investment; Successful transition from biotech towards biopharma", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ec35b4bd-1362-469d-9ef9-a2cfc04a61e7", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.03, "y": 0.21 }, "kind": "paragraph", "text": "Key considerations of drug R&D for pharma companies", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6f8bb66f-0664-4ded-af69-ed9a11a950ad", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.4, "x": 0.15, "y": 0.67 }, "kind": "quote", "text": "… Commercial attractiveness including ability to tackle unmet needs, number of suboptimal treatment, ROI, etc. will be company’s top focus as investors will only have confidence to invest in companies that can be self-sustained during the entire life cycle, from R&D to commercialization …", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b03bc6a9-3ece-4277-9195-bdae24543276", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.4, "x": 0.15, "y": 0.31 }, "kind": "quote", "text": "… Companies with multiple pipeline or marketed products are more attractive to the capital market, leading to more PEVC support and easier IPO, thus companies tend to accelerate product launch through mature path to reduce risks and cater to market’s preference …", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb08d865-e272-413a-9029-de40daaa8fbb", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "… Commercial attractiveness including ability to tackle unmet needs, number of suboptimal treatment, ROI, etc. will be company’s top focus as investors will only have confidence to invest in companies that can be self-sustained during the entire life cycle, from R&D to commercialization … - CEO, a Chinese biotech, Oct. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:01+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbd-895548f6550c", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.2, "x": 0.03, "y": 0.9 }, "kind": "source-note", "text": "Source: L.E.K. interviews and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "81093305-624d-4793-aa2a-288fd0955367", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.95, "x": 0.03, "y": 0.09 }, "kind": "title", "text": "In future, commercial attractiveness is expected to become more of a key consideration for drug R&D", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6f7af54c-7a3a-4a5f-a177-2a9d69ca6717", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.45, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Increasing Focus of More Commercially Attractive Development Areas", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "46c1c208-8efe-4dab-ae52-b4d7d7cd65af", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "027a0d0b-5eb2-4678-ad73-e7c995e3c223", "evidence": "Contrasts 'Past' (quick launch) with 'Future' (commercial attractiveness) to show strategic evolution.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 19:22:41.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "frameworkName": "before-after-framing" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 26, "type": "analysis", "title": "The chart highlights factors directly related to commercial attractiveness in green.", "function": "analyze_data", "rawType": "data_table", "block": null, "metadata": { "slideType": "data_table", "slideTypeCanon": { "name": "Data table", "slug": "data_table", "status": "active", "canonId": "019de52d-0bbd-71b9-9918-417f904abbf8", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 84, "componentCount": 9, "textChars": 1091, "nDataPoints": 8, "notes": "The chart highlights factors directly related to commercial attractiveness in green.", "elementsJson": [ "headline_text", "bar_chart_horizontal", "quote_block", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:40.932+00", "seconds": 2.772, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/26", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-26", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Ability to solve unmet clinical needs is our top priority. In addition, we would also consider if this drug would be a value-add to our current portfolio.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:01+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbd-c9d7bbc587df", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.45, "x": 0.037, "y": 0.215 }, "kind": "chart", "text": "Pharmas' key considerations when prioritizing drugs for clinical development", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.932+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aae98f9b-b4a2-4e3a-af8f-e4e74cbe519a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.037, "y": 0.89 }, "kind": "disclaimer", "text": "Note: *Survey question (for pharmas): What are the key considerations when your company prioritizes a therapeutic area or product for R&D? Source: L.E.K. survey, interviews and analysis", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.932+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "42c84e6d-ee6b-4c05-9feb-b9542f469157", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.25, "y": 0.83 }, "kind": "legend", "text": "Commercial attractiveness directly related", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.932+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5f14e689-81ba-49b1-83ed-516e7bd44854", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Percent of respondents: 85", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:01+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbd-d15adccd26e0", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.4, "x": 0.55, "y": 0.25 }, "kind": "quote", "text": "Market feedback: quotes from CEOs and VPs of Chinese biopharma companies regarding prioritization criteria.", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.932+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5d868ff6-254e-4dcc-8395-359a694133b7", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "To solve unmet clinical needs is our top priority. In addition, we would also consider if this drug would be a value-add to our current portfolio, and if we can leverage our advantage of commercial ability to launch the product efficiently ... - CEO, a Chinese biopharma, Feb. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:01+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbd-ce13e1d7e8cd", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.926, "x": 0.037, "y": 0.065 }, "kind": "title", "text": "Respondents also think that commercial attractiveness related factors are quite important when making comprehensive considerations for drug prioritization", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.932+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d24391b3-5032-4ad9-8a2a-2221bffbdef2", "parentComponentId": null }, { "bbox": { "h": 0.015, "w": 0.448, "x": 0.037, "y": 0.035 }, "kind": "title", "text": "Increasing Focus of More Commercially Attractive Development Areas", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.932+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1512ae7b-24b1-4a70-b2a0-d9824d3168c5", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Percent of respondents", "numberRaw": "85", "numberKind": "plain", "actionTitle": "Respondents also think that commercial attractiveness related factors are quite important when making comprehensive considerations for drug prioritization", "calloutText": "Ability to solve unmet clinical needs is our top priority. In addition, we would also consider if this drug would be a value-add to our current portfolio.", "numberScale": null, "numberValue": 85, "metricFamily": "survey_sentiment", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 27, "type": "analysis", "title": "The chart uses a 7-point Likert scale. The top 4 categories are highlighted in green.", "function": "analyze_data", "rawType": "market_landscape", "block": null, "metadata": { "slideType": "market_landscape", "slideTypeCanon": { "name": "Market landscape", "slug": "market_landscape", "status": "active", "canonId": "019de52d-0b6d-75db-a946-9ac362e3afc2", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 85, "componentCount": 9, "textChars": 1064, "nDataPoints": 15, "notes": "The chart uses a 7-point Likert scale. The top 4 categories are highlighted in green.", "elementsJson": [ "headline_text", "action_title", "bar_chart_horizontal", "quote_block", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:40.914+00", "seconds": 2.672, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/27", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-27", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Oncology is still going to be the most popular TA from the view of commercial attractiveness as huge unmet needs still exist for many of its indications.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-3cd0a31fd4e9", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.48, "x": 0.03, "y": 0.21 }, "kind": "chart", "text": "Perspectives on popular therapeutic areas for new clinical trial in 2022-27* (N=101)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.914+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d069647-2144-4232-abc7-162cfbe8a97c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.85, "x": 0.03, "y": 0.87 }, "kind": "disclaimer", "text": "Note: *Survey question: Which therapeutic areas do you think will be popular in terms of R&D in the next 5 years? (Please rate the level of agreement on a scale of 1 to 7...)", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.914+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "18124d69-de90-4078-8703-251b8cea4f05", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Average score: 6.4", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-47688c490ac5", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.45, "x": 0.52, "y": 0.21 }, "kind": "quote", "text": "Market feedback: Quotes from CEO, Founder, and R&D Lead regarding oncology, immunology, and rare diseases.", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.914+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e0de44e1-0dc2-46f2-a0ba-08c10c8ae9d2", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "Oncology is still going to be the most popular TA from the view of commercial attractiveness as huge unmet needs still exist for many of its indications, especially those with low survival rate, which patients will spare all efforts to cure and pay. - CEO, a Chinese biopharma, Sept. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-409ffe3a2458", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.15, "x": 0.03, "y": 0.92 }, "kind": "source-note", "text": "Source: L.E.K. survey and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.914+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a4c71452-5994-4f8c-a6a5-507ea46e35a5", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.94, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "Oncology, immunology & rheumatology, rare diseases and CNS are perceived of high commercial attractiveness by respondents in the next 5 years", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.914+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8cb84567-6134-4d7b-95e8-a3c1bd348452", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.45, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Increasing Focus of More Commercially Attractive Development Areas", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.914+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5fa41739-4eda-4063-96a2-13f7ca05ebc5", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Average score", "numberRaw": "6.4", "numberKind": "plain", "actionTitle": "Oncology, immunology & rheumatology, rare diseases and CNS are perceived of high commercial attractiveness by respondents in the next 5 years", "calloutText": "Oncology is still going to be the most popular TA from the view of commercial attractiveness as huge unmet needs still exist for many of its indications.", "numberScale": null, "numberValue": 6.4, "metricFamily": "index_score", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 28, "type": "setup", "title": "The slide uses a list format with icons to categorize qualitative feedback from interviews.", "function": "summarize", "rawType": "key_messages", "block": null, "metadata": { "slideType": "key_messages", "slideTypeCanon": { "name": "Key messages", "slug": "key_messages", "status": "active", "canonId": "019de52d-0712-703f-89f5-bda6688faf3f", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 86, "componentCount": 11, "textChars": 1656, "nDataPoints": 0, "notes": "The slide uses a list format with icons to categorize qualitative feedback from interviews.", "elementsJson": [ "icon_grid", "quote_block" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "at": "2026-07-17 03:24:02.541+00", "seconds": 3.755, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/28", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-28", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "list", "text": "Return on investment: Total cost inputted in R&D compared with revenue generated", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:02.541+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "00de5ae7-9427-4d56-bd28-9cfce2e6a509", "parentComponentId": null }, { "bbox": null, "kind": "list", "text": "Feasibility to collaborate: Ability to find and collaborate with capable partners", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:02.541+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10be9b46-9ca0-4875-b109-398f5a4ba1b9", "parentComponentId": null }, { "bbox": null, "kind": "list", "text": "Company expertise: Talent pool, R&D and go-to-market abilities", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:02.541+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a0966930-5730-42b1-a0e1-9815344d1a34", "parentComponentId": null }, { "bbox": null, "kind": "paragraph", "text": "Other factors considered when prioritizing drugs for clinical development", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": "description", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:02.541+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1f9be970-445f-48f6-a721-5bda53d68efc", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "Favorable clinical trial regulatory requirements also contribute to oncology's future attractiveness – as a single-arm study is allowed for registration under certain circumstances, leading to trial risk mitigating, cost reduction and better ROI", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:02.541+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "92490423-2cbe-4498-aa92-82306d4c1968", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "In an efficient ecosystem, traditional pharmas should leverage their commercialization and manufacturing ability, whereas biotechs should take advantage of their research ability to focus on truly innovative products. The division of roles is going to accelerate innovative products' speed-to-market", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:02.541+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9cc03d3b-d5ed-4833-8ee2-316b8f72518f", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "We are able to partner with a leading MNC for commercialization of a core product. Combining our leading innovative R&D capabilities and partner's extensive channel network, it's a win-win for us to fulfill each other's needs, and to bring local high-quality innovative drugs to domestic patients", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:02.541+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b521c97c-1661-4264-b404-5ca74032b64a", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "Favorable clinical trial regulatory requirements also contribute to oncology's future attractiveness – as a single-arm study is allowed for registration under certain circumstances, leading to trial risk mitigating, cost reduction and better ROI ... (CEO, a Chinese biopharma, Sept. 2022)", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:01+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbd-ea661a7737ad", "parentComponentId": null }, { "bbox": null, "kind": "source-note", "text": "Source: L.E.K. interviews and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": "source-note", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:02.541+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "20f1d85f-55ca-41fe-a413-d7c39c458042", "parentComponentId": null }, { "bbox": null, "kind": "title", "text": "Increasing Focus of More Commercially Attractive Development Areas", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:02.541+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5b476ff0-d742-473c-a268-53bcc465e476", "parentComponentId": null }, { "bbox": null, "kind": "title", "text": "Other factors considered for drug prioritization include return on investment, company expertise, and feasibility to collaborate", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-07-17 03:24:02.541+00", "model": "google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "adfa4752-c141-47e4-bbbd-048501e70cee", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 29, "type": "setup", "function": "front_matter", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 20, "componentCount": 2, "textChars": 438, "nDataPoints": 0, "notes": null, "elementsJson": [ "bullet_list" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:40.421+00", "seconds": 2.014, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/29", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-29", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.52, "w": 0.61, "x": 0.038, "y": 0.218 }, "kind": "list", "text": "Context of clinical trial development in China\nFuture strategic trends of clinical trial development in China\nDevelopment of More Innovative and Differentiated Therapies\nIncreasing Focus of More Commercially Attractive Development Areas\nAdoption of Smarter Clinical Trial Tools\nA Two-way Pursuit: Globalization of Chinese Biopharma & Evolution of MNC China R&D strategy\nNext step questions\nResources and references\nAbout the authors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.421+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "105112ee-4f02-429f-b0bb-b5b6b3a669ec", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.085, "x": 0.038, "y": 0.143 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:40.421+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "020c506a-a54d-4688-862a-31f65df8f99a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 30, "type": "analysis", "title": "The slide uses a structured table to map trends to operational/technical complexity and their specific implications.", "function": "establish_context", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "sparse", "densityScore": 21, "componentCount": 4, "textChars": 303, "nDataPoints": 0, "notes": "The slide uses a structured table to map trends to operational/technical complexity and their specific implications.", "elementsJson": [ "headline_text", "comparison_table", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:43.983+00", "seconds": 5.332, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/30", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-30", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.19, "x": 0.77, "y": 0.83 }, "kind": "callout", "text": "XX Smart and digital technology needs", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.983+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "68675a16-d758-4696-ab56-df4bf95ab96d", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.037, "y": 0.89 }, "kind": "source-note", "text": "Note: *SoC: Standard of Care. Source: L.E.K. research and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.983+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e1fb9e62-efc3-4133-90fe-f0406f29c7e3", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.92, "x": 0.037, "y": 0.248 }, "kind": "table", "text": "Mega trends table with columns: Mega trends, Description, Implications for clinical trial", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.983+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "21593ee0-d990-4b40-a9cf-8cd6618732aa", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.85, "x": 0.037, "y": 0.06 }, "kind": "title", "text": "Increasing complexity is the mega trend of clinical trial, driving the needs for smart and digital technologies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.983+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "126ad754-68e7-43b7-9692-7986ea389ec6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 31, "type": "setup", "title": "The slide uses a chronological framework to explain the shift from paper-based to integrated digital platforms in clinical trials.", "function": "establish_context", "rawType": "timeline", "block": null, "metadata": { "slideType": "timeline", "slideTypeCanon": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-0851-75eb-b758-ea2965e7739a", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 7, "textChars": 1164, "nDataPoints": 0, "notes": "The slide uses a chronological framework to explain the shift from paper-based to integrated digital platforms in clinical trials.", "elementsJson": [ "headline_text", "action_title", "timeline_visual", "bullet_list", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:43.437+00", "seconds": 4.688, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/31", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-31", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.92, "x": 0.037, "y": 0.22 }, "kind": "diagram", "text": "Development timeline of clinical trial digitalization in China*", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.437+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c1b8a830-428c-4443-b19d-3296baab99f2", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.08, "y": 0.4 }, "kind": "list", "text": "Emerging Stage: Clinical trial data was mainly hand-written and paper-based; Large waves of clinical trials starting in late 20th century led to a burst in trial data, further driving the needs for data management", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.437+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9ef7774d-d25a-48b8-92fc-6f415f2d952c", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.38, "y": 0.4 }, "kind": "list", "text": "Rapid Growth: NMPA's requirement on clinical trial data quality and governance facilitated the adoption of digital tools; EDC began to be adopted with other digital tools such as CTMS, eTMF, IWRS and PVS emerging", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.437+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ca5cdce4-3af6-4bc9-9f2a-9b5a8cd89775", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.68, "y": 0.4 }, "kind": "list", "text": "Platforms & Integration: Pharma and trial sponsors' increasing requirement for higher efficiency in clinical trials drives the need of smarter digital platform integrating different digital tools with better user interaction", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.437+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f98636d1-63b3-4218-97a9-f82319c7d3af", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.037, "y": 0.88 }, "kind": "source-note", "text": "Note: *EDC: Electronic Data Capture, CTMS: Clinical Trial Management System, eTMF: Electronic Trial Master File, IWRS: Interactive Web Response System, PVS: Pharmacovigilance System. Source: NMPA, EO Intelligence, L.E.K. analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.437+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "642b8b3e-b0f4-4e18-abe5-7da5c1c83805", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.92, "x": 0.037, "y": 0.06 }, "kind": "title", "text": "Clinical trial digitalization has experienced rapid evolution over the past 7-8 years, and has been calling for platforms & integration to further improve trial quality and efficiency", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.437+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "926bc982-a551-4a37-9b59-3b459cf444db", "parentComponentId": null }, { "bbox": { "h": 0.017, "w": 0.25, "x": 0.037, "y": 0.033 }, "kind": "title", "text": "Adoption of Smarter Clinical Trial Tools", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.437+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e1d2f40a-4166-4a4d-9b16-a73d01becbe5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "1ab21dee-cc19-462c-8204-674faba03cd8", "evidence": "The slide presents a chronological progression of events across three distinct time periods.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 19:22:43.437+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 32, "type": "analysis", "title": "The chart combines a horizontal bar chart for penetration rates with a stakeholder usage matrix.", "function": "analyze_data", "rawType": "data_table", "block": null, "metadata": { "slideType": "data_table", "slideTypeCanon": { "name": "Data table", "slug": "data_table", "status": "active", "canonId": "019de52d-0bbd-71b9-9918-417f904abbf8", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 7, "textChars": 504, "nDataPoints": 11, "notes": "The chart combines a horizontal bar chart for penetration rates with a stakeholder usage matrix.", "elementsJson": [ "bar_chart_horizontal", "comparison_table", "icon_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:44.573+00", "seconds": 5.624, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/32", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-32", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "EDC, CTMS, eTMF and PVS technologies are being widely adopted in China clinical trials.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:01+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbd-fea03f761f4f", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.25, "x": 0.037, "y": 0.215 }, "kind": "chart", "text": "Penetration of digital and smart clinical trial technologies", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1fde3691-2d21-411e-b213-eab859f8c202", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Percent of respondents: 76%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:01+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-017cda067c57", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.037, "y": 0.88 }, "kind": "source-note", "text": "Note: *Survey question: Which of the following digital and smart clinical trial technologies have you used? Source: EO Intelligence, L.E.K. survey and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "84754755-6fc0-4d1b-9691-7cf180fb0d0d", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.45, "x": 0.51, "y": 0.215 }, "kind": "table", "text": "Related technologies used by key stakeholders", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "671a4f1a-450d-4917-afb0-96a8fd9d4626", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.75, "x": 0.037, "y": 0.105 }, "kind": "title", "text": "EDC, CTMS, eTMF and PVS technologies are being widely adopted in China clinical trials", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8a865b14-ba1f-46e3-820b-53f806fe23e1", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.25, "x": 0.037, "y": 0.033 }, "kind": "title", "text": "Adoption of Smarter Clinical Trial Tools", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.573+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "99da9c56-0ade-4b70-9969-7097ed18c1bf", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Percent of respondents", "numberRaw": "76%", "numberKind": "percent", "actionTitle": "EDC, CTMS, eTMF and PVS technologies are being widely adopted in China clinical trials", "calloutText": "EDC, CTMS, eTMF and PVS technologies are being widely adopted in China clinical trials.", "numberScale": null, "numberValue": 76, "metricFamily": "survey_sentiment", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 33, "type": "resolution", "title": "Includes bilingual survey methodology notes.", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 89, "componentCount": 11, "textChars": 1484, "nDataPoints": 2, "notes": "Includes bilingual survey methodology notes.", "elementsJson": [ "headline_text", "big_number", "quote_block", "icon_grid", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:43.088+00", "seconds": 3.601, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/33", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-33", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Majority of respondents believe smart and digital tools will be indispensable with increasing demand of smart trials, and 33% even believe that revolutionary impact will be brought in next 10 years", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:02+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-3881eed95dae", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.08, "x": 0.12, "y": 0.65 }, "kind": "metric", "text": "33%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.088+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c0b3f35-3e1b-4b29-986e-a4155ff86ce4", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.08, "x": 0.12, "y": 0.35 }, "kind": "metric", "text": "71%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.088+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c0fdc7f4-1343-47b9-bbdb-4a505509831d", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "respondent agreement: 71%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:02+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-4225d15e229c", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.5, "x": 0.037, "y": 0.215 }, "kind": "paragraph", "text": "Perspectives on future trends and impact of clinical trial digitalization and smartness", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.088+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "85d6a1f3-286d-46ea-b9df-22adda7f97da", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.45, "x": 0.49, "y": 0.31 }, "kind": "quote", "text": "… I think most digital technologies can offer value-adds to clinical trials in helping increase efficiency. I also hope that in the future, more advanced tools can be available, e.g., reducing patient enrollment base (such as from 30k to 2k) with the help of computer simulation of enormous historical data …", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.088+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10ca5adc-9afe-4aac-b88a-f675df009997", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.45, "x": 0.49, "y": 0.62 }, "kind": "quote", "text": "… Smart and digital technologies will definitely revolutionize clinical trials because they significantly improve efficiency and data quality of the trials through emerging applications, such as file management system and AI monitoring …", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.088+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9d90ca66-3fad-4f3c-a156-0ed5a0496f3b", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "I think most digital technologies can offer value-adds to clinical trials in helping increase efficiency. I also hope that in the future, more advanced tools can be available, e.g., reducing patient enrollment base (such as from 30k to 2k) with the help of computer simulation of enormous historical data ... - R&D Lead, a leading MNC pharma, Sept. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:02+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-3dbd9478e49f", "parentComponentId": null }, { "bbox": { "h": 0.015, "w": 0.15, "x": 0.037, "y": 0.905 }, "kind": "source-note", "text": "Source: L.E.K. survey and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.088+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd2d14a4-ea7a-4488-9c42-d687df0624d6", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.92, "x": 0.037, "y": 0.06 }, "kind": "title", "text": "Majority of respondents believe smart and digital tools will be indispensable with increasing demand of smart trials, and 33% even believe that revolutionary impact will be brought in next 10 years", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.088+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5a08fe9b-fd38-44e2-bf81-a671211d5113", "parentComponentId": null }, { "bbox": { "h": 0.015, "w": 0.25, "x": 0.037, "y": 0.033 }, "kind": "title", "text": "Adoption of Smarter Clinical Trial Tools", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.088+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "102e1dfc-c6ba-4514-95c1-0f39b678e7ea", "parentComponentId": null } ], "metrics": [ { "metricRaw": "respondent agreement", "numberRaw": "71%", "numberKind": "percent", "actionTitle": "Majority of respondents believe smart and digital tools will be indispensable with increasing demand of smart trials, and 33% even believe that revolutionary impact will be brought in next 10 years", "calloutText": "Majority of respondents believe smart and digital tools will be indispensable with increasing demand of smart trials, and 33% even believe that revolutionary impact will be brought in next 10 years", "numberScale": null, "numberValue": 71, "metricFamily": "survey_sentiment", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 34, "type": "analysis", "title": "The slide uses a combination of quantitative survey data and qualitative expert quotes to validate the trend towards smart clinical trial formats.", "function": "summarize", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 8, "textChars": 1014, "nDataPoints": 4, "notes": "The slide uses a combination of quantitative survey data and qualitative expert quotes to validate the trend towards smart clinical trial formats.", "elementsJson": [ "headline_text", "bar_chart_horizontal", "quote_block", "icon_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:43.024+00", "seconds": 3.303, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/34", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-34", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.45, "x": 0.037, "y": 0.21 }, "kind": "chart", "text": "Perspectives on other future trends of clinical trial digitalization and smartness", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.024+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bfad30d5-92ac-4a89-b686-accae46fa532", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Percent of respondents: 52", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:01+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-20793311b1f1", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.45, "x": 0.51, "y": 0.58 }, "kind": "quote", "text": "... We believe that digitalization would bring revolutionary change... - R&D Lead, a leading MNC pharma, Sept. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.024+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "146fb9bf-36df-4ce0-b3f7-056ca5180d4b", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.45, "x": 0.51, "y": 0.21 }, "kind": "quote", "text": "Market feedback: ... In the future, I think more new smart trial formats may be adopted... - R&D Lead, a leading MNC pharma, Sept. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.024+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "327a9c7f-0273-46fc-98a0-cc46430431e1", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "In the future, I think more new smart trial formats may be adopted. Taking wearable devices as an example, it can collect more patient data live compared with mere onsite data recording, helping us to better understand drug efficacy. - R&D Lead, a leading MNC pharma, Sept. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:01+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-1d25d663ae21", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.75, "x": 0.037, "y": 0.88 }, "kind": "source-note", "text": "Note: *Survey question: Which of the following statements do you most agree with regarding key trends of clinical trial digitalization and smartness in China? Source: L.E.K. survey and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.024+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f0fd67f7-39c8-4b7b-b1df-def8e5d16de5", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.87, "x": 0.037, "y": 0.058 }, "kind": "title", "text": "Nearly half of the respondents also believe there will be increasing data interaction needs and emergence of new smart trial format going forward", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.024+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6ae6c0d6-0655-4707-a430-67cbd7132b00", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.037, "y": 0.033 }, "kind": "title", "text": "Adoption of Smarter Clinical Trial Tools", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.024+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "890f0e88-d97b-48fa-9145-0e8e5f84bfa3", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Percent of respondents", "numberRaw": "52", "numberKind": "plain", "actionTitle": "Nearly half of the respondents also believe there will be increasing data interaction needs and emergence of new smart trial format going forward", "calloutText": null, "numberScale": null, "numberValue": 52, "metricFamily": "survey_sentiment", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 35, "type": "setup", "title": "The slide tracks the progression of Chinese regulatory guidelines (CDE) towards patient-centric and remote clinical trial methodologies.", "function": "establish_context", "rawType": "timeline", "block": null, "metadata": { "slideType": "timeline", "slideTypeCanon": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-0851-75eb-b758-ea2965e7739a", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 10, "textChars": 1162, "nDataPoints": 0, "notes": "The slide tracks the progression of Chinese regulatory guidelines (CDE) towards patient-centric and remote clinical trial methodologies.", "elementsJson": [ "headline_text", "timeline_visual", "bullet_list", "paragraph" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:43.256+00", "seconds": 3.432, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/35", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-35", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Under the background of COVID-19, though no specific policy or guideline for virtual trial / DCT has been launched so far, regulatory agency has started to take DCT into consideration for policy design with the guideline of patient-centric clinical trial", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:02+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-799f2b03e90a", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.92, "x": 0.037, "y": 0.25 }, "kind": "diagram", "text": "Timeline of CDE guidelines", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5d1b9ef9-839e-4e24-9cbc-d7b3b768db41", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.75, "y": 0.42 }, "kind": "list", "text": "Aug 2022: Technical Guiding Principles for Patient Centered Clinical Trial Implementation (Draft for Comments)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "23af371f-4cc0-40c4-a2b6-bc6f5deb4ac7", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.27, "y": 0.42 }, "kind": "list", "text": "Nov 2021: Guiding Principles for Clinical Value-Oriented Clinical Development of Oncology Drugs", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "367b358c-a8b7-413f-9d63-db842713a46a", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.037, "y": 0.42 }, "kind": "list", "text": "Jul 2020: Guiding Principles for the Management of Drug Clinical Trials during the COVID-19 (Pilot Version)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "528cab24-bc16-4537-a3ca-f70fe5e3af13", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.51, "y": 0.42 }, "kind": "list", "text": "Aug 2022: Technical Guiding Principles for Patient Centered Clinical Trial Design (Draft for Comments)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "58e58f13-c74a-4d29-b472-d71d015fdecb", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.92, "x": 0.037, "y": 0.78 }, "kind": "paragraph", "text": "Under the background of COVID-19, though no specific policy or guideline for virtual trial / DCT has been launched so far, regulatory agency has started to take DCT into consideration for policy design with the guideline of patient-centric clinical trial", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "01582da4-6df5-407a-805a-bf8987324b8d", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.15, "x": 0.037, "y": 0.91 }, "kind": "source-note", "text": "Source: CDE, L.E.K. analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "beade840-4098-4d4f-9494-66f617eae30b", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.92, "x": 0.037, "y": 0.06 }, "kind": "title", "text": "Virtual trial / DCT: Virtual clinical trial has indeed become a heated topic, which has also obtained attention from regulatory authority recently", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0c8bab59-8219-4ae0-a092-77fe0dfc3d69", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.037, "y": 0.035 }, "kind": "title", "text": "Adoption of Smarter Clinical Trial Tools", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff359762-7591-4e50-8b12-e7477f9f52ed", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "d4244693-e451-4d75-ae1a-4b93904335a4", "evidence": "Chronological progression of regulatory guidelines", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 19:22:43.256+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 35, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 36, "type": "setup", "title": "The slide uses a split-layout to contrast positive drivers against negative barriers.", "function": "compare_options", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_options", "functionCanon": { "name": "Compare options", "slug": "compare_options", "status": "active", "canonId": "019de52d-167f-7038-aebc-70a9d2e0e33b", "version": 1, "description": null }, "density": "balanced", "densityScore": 47, "componentCount": 6, "textChars": 576, "nDataPoints": 0, "notes": "The slide uses a split-layout to contrast positive drivers against negative barriers.", "elementsJson": [ "headline_text", "icon_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:42.812+00", "seconds": 2.885, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/36", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-36", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.45, "x": 0.037, "y": 0.27 }, "kind": "list", "text": "Drivers: Improving telemedicine technology, Lower cost, Higher coverage of patient, Lower patient drop-out rate", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.812+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "021e41b2-361a-4bf4-a840-4f0040cc7497", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.45, "x": 0.52, "y": 0.27 }, "kind": "list", "text": "Barriers: Policy uncertainty, Difficulty in execution, Modality limitation, Low patient awareness, Less global successful experience", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.812+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "538859fb-89a1-4730-88c4-d937932b102a", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.35, "x": 0.037, "y": 0.21 }, "kind": "paragraph", "text": "Virtual clinical trial future penetration drivers vs. barriers", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.812+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8f4a5a57-a772-4bae-b0ba-eaf04205c8a0", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.15, "x": 0.037, "y": 0.9 }, "kind": "source-note", "text": "Source: L.E.K. interviews and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.812+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a5828310-179f-4d94-9a82-3b8b4fbb5234", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.92, "x": 0.037, "y": 0.06 }, "kind": "title", "text": "Virtual trial / DCT: There exist both drivers and barriers for the future development of virtual clinical trial with efficiency improvement as main driver and policy uncertainty as main concern", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.812+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7753a5c4-bad0-457f-8002-004e0c0464b0", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.037, "y": 0.033 }, "kind": "title", "text": "Adoption of Smarter Clinical Trial Tools", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:42.812+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "801c4cec-7e37-4e82-baf7-d079b29c9d64", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "42218049-4531-4792-9b10-6900ea288852", "evidence": "The slide explicitly contrasts drivers vs barriers in a side-by-side layout.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 19:22:42.812+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "comparison_frame" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 37, "type": "analysis", "title": "The slide uses a visual bridge to connect the 'Likely'/'Highly Likely' and 'Unlikely'/'Not Possible' segments of the survey to their respective rationales.", "function": "analyze_data", "rawType": "data_table", "block": null, "metadata": { "slideType": "data_table", "slideTypeCanon": { "name": "Data table", "slug": "data_table", "status": "active", "canonId": "019de52d-0bbd-71b9-9918-417f904abbf8", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 70, "componentCount": 7, "textChars": 838, "nDataPoints": 19, "notes": "The slide uses a visual bridge to connect the 'Likely'/'Highly Likely' and 'Unlikely'/'Not Possible' segments of the survey to their respective rationales.", "elementsJson": [ "headline_text", "bar_chart_stacked", "bar_chart_horizontal", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:43.091+00", "seconds": 3.135, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/37", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-37", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Able to live monitor trial data is the primary rationale for adoption (79%), while lack of guidelines from NMPA/CDE (53%) is the leading barrier.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:02+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-a422b7ebfc34", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.45, "x": 0.5, "y": 0.22 }, "kind": "chart", "text": "Rationales on conducting / not conducting virtual trial / DCT", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.091+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac70c64f-f635-4797-9321-e963d83d85b4", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.35, "x": 0.038, "y": 0.22 }, "kind": "chart", "text": "Pharmas' likelihood to conduct virtual trial / DCT in China in 2-3 years", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.091+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d8b90ef3-34d0-4344-bbb4-a2bc608a3722", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.92, "x": 0.038, "y": 0.85 }, "kind": "disclaimer", "text": "Note: *Survey question: What is the likelihood of your company to conduct virtual trial / DCT in 2-3 years? **Survey question: What are the key reasons that your company is likely to conduct virtual trial / DCT in China? What are the key reason that your company is not likely to conduct virtual trial / DCT in China?", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.091+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5f178162-7444-4576-b644-e0b609098db7", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Percent of respondents: 79%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:02+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-a9d81c5d8d71", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.038, "y": 0.9 }, "kind": "source-note", "text": "Source: L.E.K. survey and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.091+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bde7e4da-a195-41d7-9dd9-dc2356ba7e8b", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.92, "x": 0.038, "y": 0.06 }, "kind": "title", "text": "Virtual trial / DCT: Respondents also show split attitude on likelihood to conduct virtual trial / DCT in China, with ability to live monitor trial data as key rationale for adoption", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.091+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6f9bb83a-4b3f-4526-bd93-f3266647264d", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Percent of respondents", "numberRaw": "79%", "numberKind": "percent", "actionTitle": "Virtual trial / DCT: Respondents also show split attitude on likelihood to conduct virtual trial / DCT in China, with ability to live monitor trial data as key rationale for adoption", "calloutText": "Able to live monitor trial data is the primary rationale for adoption (79%), while lack of guidelines from NMPA/CDE (53%) is the leading barrier.", "numberScale": null, "numberValue": 79, "metricFamily": "survey_sentiment", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 38, "type": "setup", "function": "summarize", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "sparse", "densityScore": 20, "componentCount": 2, "textChars": 438, "nDataPoints": 0, "notes": null, "elementsJson": [ "bullet_list" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:41.865+00", "seconds": 1.824, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/38", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-38", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.51, "w": 0.63, "x": 0.038, "y": 0.217 }, "kind": "list", "text": "Context of clinical trial development in China\nFuture strategic trends of clinical trial development in China\nDevelopment of More Innovative and Differentiated Therapies\nIncreasing Focus of More Commercially Attractive Development Areas\nAdoption of Smarter Clinical Trial Tools\nA Two-way Pursuit: Globalization of Chinese Biopharma & Evolution of MNC China R&D strategy\nNext step questions\nResources and references\nAbout the authors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.865+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ffa2bdb8-f71d-4c44-a5a3-693539fe2e52", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.085, "x": 0.038, "y": 0.144 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:41.865+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d310068b-3279-4b33-9ee1-b5bdf5a310ad", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 39, "type": "analysis", "title": "The slide uses a circular flow diagram to represent a reciprocal relationship between two market actors.", "function": "present_framework", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 61, "componentCount": 7, "textChars": 792, "nDataPoints": 0, "notes": "The slide uses a circular flow diagram to represent a reciprocal relationship between two market actors.", "elementsJson": [ "headline_text", "process_diagram", "icon_grid" ], "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:47.258+00", "seconds": 7.132, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/39", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-39", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Chinese domestic biopharmas are actively going overseas to seek revenue uplift and global validation; MNC pharmas are actively picking up Chinese drug assets and investing in early-stage innovation through strengthening local cooperation.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-c71d913fdfe8", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "diagram", "text": "Two-way pursuit of Chinese biopharmas and MNC pharmas", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:47.258+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5799205d-8f21-47e3-91de-6aace6b1ad96", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.38, "y": 0.4 }, "kind": "paragraph", "text": "Chinese domestic biopharmas are actively going overseas to seek revenue uplift and global validation", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:47.258+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3663f3ae-698e-4989-9bf4-19b0fbf36e40", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.38, "y": 0.6 }, "kind": "paragraph", "text": "MNC pharmas are actively picking up Chinese drug assets and investing in early-stage innovation through strengthening local cooperation", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:47.258+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6c3b1622-ff70-44f3-9c96-b6187447fb14", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.1, "x": 0.03, "y": 0.9 }, "kind": "source-note", "text": "Source: L.E.K. analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:47.258+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9d759138-021a-4f5c-97fa-15464b0cffa8", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "Globalization of Chinese biopharma and the evolution of MNC China R&D strategy are also the two noteworthy trends of clinical trial development in China", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:47.258+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a7a640e4-b31f-4229-9ad1-84da2156055d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "A Two-way Pursuit: Globalization of Chinese Biopharma & Evolution of MNC China R&D strategy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:47.258+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d6b95fb0-336c-4a66-a266-e4b5682a3885", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "08610041-4b18-4155-b1af-91454a90bf4d", "evidence": "Circular flow diagram representing a two-way mutually reinforcing relationship.", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 19:22:47.258+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "frameworkName": "flywheel" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 40, "type": "analysis", "title": "Survey data from IQVIA/L.E.K. Consulting (N=56).", "function": "quantify_impact", "rawType": "market_landscape", "block": null, "metadata": { "slideType": "market_landscape", "slideTypeCanon": { "name": "Market landscape", "slug": "market_landscape", "status": "active", "canonId": "019de52d-0b6d-75db-a946-9ac362e3afc2", "version": 1, "description": null }, "function": "quantify_impact", "functionCanon": { "name": "Quantify impact", "slug": "quantify_impact", "status": "active", "canonId": "019de52d-1630-720d-b57d-fa7f76bebd8d", "version": 1, "description": null }, "density": "dense", "densityScore": 67, "componentCount": 7, "textChars": 848, "nDataPoints": 4, "notes": "Survey data from IQVIA/L.E.K. Consulting (N=56).", "elementsJson": [ "headline_text", "bar_chart_stacked", "icon_grid", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:55.561+00", "seconds": 15.258, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/40", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-40", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "Globalization is increasingly an imperative for Chinese biopharmas with 95% of respondents either conducted or expressed interest in ex-China clinical trials.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-1c3eac1b5db5", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.45, "x": 0.508, "y": 0.215 }, "kind": "chart", "text": "Chinese biopharmas' attitude towards ex-China clinical trial", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:55.561+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "915592fa-a7a1-4a48-82a5-4b6143a03cb5", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.45, "x": 0.04, "y": 0.21 }, "kind": "list", "text": "Massive and lucrative overseas markets with high reward on innovation, e.g., U.S. Competency improvement brought by participating in the most regulated and competitive markets Global validation and market capitalization boost", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:55.561+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "806ac4af-26c4-40e8-8bb9-35b53d75850d", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Percent of respondents: 95%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-23902fb3c0e8", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.037, "y": 0.88 }, "kind": "source-note", "text": "Note: *Survey question (for Chinese biopharmas): What is your company's attitude towards conducting clinical trials overseas? 您所在企业对开展海外临床试验的态度是? Source: IQVIA, L.E.K. survey and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:55.561+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "221839d3-7841-49bf-aec3-bd16789fd2bb", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.92, "x": 0.037, "y": 0.06 }, "kind": "title", "text": "Globalization is increasingly an imperative for Chinese biopharmas with 95% of respondents either conducted or expressed interest in ex-China clinical trials", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:55.561+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12cf80d4-decd-4300-9be8-ec0b732dfacb", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.23, "x": 0.037, "y": 0.033 }, "kind": "title", "text": "Globalization of Chinese Biopharma", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:55.561+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff6dd212-b83f-44b7-aa54-5711a87873d9", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Percent of respondents", "numberRaw": "95%", "numberKind": "percent", "actionTitle": "Globalization is increasingly an imperative for Chinese biopharmas with 95% of respondents either conducted or expressed interest in ex-China clinical trials", "calloutText": "Globalization is increasingly an imperative for Chinese biopharmas with 95% of respondents either conducted or expressed interest in ex-China clinical trials.", "numberScale": null, "numberValue": 95, "metricFamily": "survey_sentiment", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 41, "type": "analysis", "title": "The slide uses stacked bar charts to show ranking preferences (Top 1, 2, 3) for destinations and simple bar charts for decision factors.", "function": "analyze_data", "rawType": "market_landscape", "block": null, "metadata": { "slideType": "market_landscape", "slideTypeCanon": { "name": "Market landscape", "slug": "market_landscape", "status": "active", "canonId": "019de52d-0b6d-75db-a946-9ac362e3afc2", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 7, "textChars": 701, "nDataPoints": 14, "notes": "The slide uses stacked bar charts to show ranking preferences (Top 1, 2, 3) for destinations and simple bar charts for decision factors.", "elementsJson": [ "headline_text", "bar_chart_stacked", "bar_chart_horizontal", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:43.293+00", "seconds": 2.874, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/41", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-41", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.58, "w": 0.46, "x": 0.5, "y": 0.21 }, "kind": "chart", "text": "Key considerations on choosing clinical trial destination outside China", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd488f72-51d6-4102-8f60-58c9338b926c", "parentComponentId": null }, { "bbox": { "h": 0.58, "w": 0.43, "x": 0.037, "y": 0.21 }, "kind": "chart", "text": "Evaluation of clinical trial destination attractiveness outside China", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "afe0fcf6-0b83-4c5e-abcc-c28c8016a409", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.92, "x": 0.037, "y": 0.85 }, "kind": "disclaimer", "text": "Note: *Survey question (for Chinese biopharmas): Please select and rank the top 3 countries that are most attractive for conducting overseas clinical trials. **Survey question (for Chinese biopharmas): What are the main reasons that you choose Top 1 clinical trial destination country in the last question?", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "59c4302e-b4e1-4641-b17a-34a177d1d9eb", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.12, "x": 0.31, "y": 0.775 }, "kind": "legend", "text": "Top 1, Top 2, Top 3", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fb575a3c-30c0-40a2-8517-d6d29713133e", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Percent of respondents: 81", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:04+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-f67c51409333", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.92, "x": 0.037, "y": 0.06 }, "kind": "title", "text": "U.S., Australia and Europe are the most attractive destinations outside China for Chinese biopharmas, considering MNC collaboration, clinical trial duration and speed-to-market", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4d37287f-45a4-418f-be51-3a7582ba4368", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.037, "y": 0.035 }, "kind": "title", "text": "Globalization of Chinese Biopharma", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.293+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "05df3d0e-1f2d-4d98-8d71-93b2d9aec87b", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Percent of respondents", "numberRaw": "81", "numberKind": "plain", "actionTitle": "U.S., Australia and Europe are the most attractive destinations outside China for Chinese biopharmas, considering MNC collaboration, clinical trial duration and speed-to-market", "calloutText": null, "numberScale": null, "numberValue": 81, "metricFamily": "survey_sentiment", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 42, "type": "setup", "function": "summarize", "rawType": "testimonial", "block": null, "metadata": { "slideType": "testimonial", "slideTypeCanon": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52d-0a2d-7782-8a48-7e84df92cc97", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 71, "componentCount": 9, "textChars": 714, "nDataPoints": 0, "notes": null, "elementsJson": [ "headline_text", "icon_grid", "quote_block" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:48.881+00", "seconds": 8.447, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/42", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-42", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.08, "x": 0.037, "y": 0.29 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:48.881+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac3c70ec-eab1-4c1c-b6b1-3efd6b123fa3", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.275, "x": 0.037, "y": 0.215 }, "kind": "paragraph", "text": "Factors considered for oversea clinical trial", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:48.881+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "66330655-7740-4db8-94e1-c7dfe1302b71", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.18, "x": 0.13, "y": 0.705 }, "kind": "quote", "text": "Active communication with regulatory agencies", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:48.881+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "618ffee9-f2f9-4a37-8c06-5caff98d310e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.18, "x": 0.13, "y": 0.325 }, "kind": "quote", "text": "Careful prioritization of trial destination", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:48.881+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "734c203a-6c17-47a1-850d-ae5ac8f8c625", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.145, "y": 0.515 }, "kind": "quote", "text": "Oversea local team setup", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:48.881+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "994e378e-089c-4e7f-84d5-c352fd4e8705", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "Companies should prioritize their oversea clinical trial destinations wisely. Factors such as patient base, local regulations, geopolitics, and commercial potential in each destination should be thoroughly considered when designing the ex-China trial road map - CEO & CMO, a Chinese biotech, Nov. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbe-ea0e0baaceb5", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.2, "x": 0.037, "y": 0.9 }, "kind": "source-note", "text": "Source: Yicai, L.E.K. interviews and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:48.881+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "afdcdcfe-069d-4648-85e6-e863dcb5048d", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.925, "x": 0.037, "y": 0.06 }, "kind": "title", "text": "In order to succeed in oversea clinical trial, careful prioritization of destination, oversea local team setup, and active communication with regulatory agencies are anticipated", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:48.881+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "396457d0-58d4-4970-bcf1-de2e81717d85", "parentComponentId": null }, { "bbox": { "h": 0.015, "w": 0.236, "x": 0.037, "y": 0.035 }, "kind": "title", "text": "Globalization of Chinese Biopharma", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:48.881+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cfb5c5eb-2714-4a29-9feb-ca33fc632c5d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 43, "type": "analysis", "title": "The chart displays quarterly deal numbers, showing significant volatility but a clear increase in peak deal activity post-2018.", "function": "analyze_data", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 51, "componentCount": 5, "textChars": 665, "nDataPoints": 47, "notes": "The chart displays quarterly deal numbers, showing significant volatility but a clear increase in peak deal activity post-2018.", "elementsJson": [ "area_chart", "footnote" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:47.518+00", "seconds": 6.918, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/43", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-43", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.583, "w": 0.926, "x": 0.037, "y": 0.217 }, "kind": "chart", "text": "China pharma and biotech license-out deals (2011 Q1-22 Q3)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Area chart", "slug": "area", "status": "active", "canonId": "019de52c-ff89-71e0-911e-5cab78b90f53", "version": 1, "description": null }, "framework": null }, "subkind": "area", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:47.518+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a4266705-2fb2-4fa4-8291-61206f4ae71b", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Quarterly deal numbers", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-d33d22f0d107", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.845, "x": 0.037, "y": 0.867 }, "kind": "source-note", "text": "Note: *Cortellis screening criteria: license-out deals of pharmas and biotechs with deal's principal HQ in mainland China, partner HQ outside mainland China, non-terminated deals (active, completed or pending), and agreement type of Company-JV, Company-M&A, Drug-Asset divestment, Drug-Commercialization license, Development/Drug-Commercialization license\nSource: Cortellis Deal Intelligence, L.E.K. analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:47.518+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8719c53c-7f40-4356-b110-c995446eef2d", "parentComponentId": null }, { "bbox": { "h": 0.042, "w": 0.926, "x": 0.037, "y": 0.061 }, "kind": "title", "text": "Chinese innovations are now being validated on the international stage, as their global rights are being picked up by oversea counterparts ...", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:47.518+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5cfd8e49-7a0d-4d03-808c-9971b4dc4c4d", "parentComponentId": null }, { "bbox": { "h": 0.018, "w": 0.248, "x": 0.037, "y": 0.033 }, "kind": "title", "text": "Evolution of MNC China R&D strategy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:47.518+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d30dbf70-66db-4a57-a473-ed301da0078e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 44, "type": "evidence", "title": "The slide highlights the trend of international pharma companies licensing innovative assets from Chinese biotech firms.", "function": "illustrate_case", "rawType": "client_example", "block": null, "metadata": { "slideType": "client_example", "slideTypeCanon": { "name": "Client example", "slug": "client_example", "status": "active", "canonId": "019de52d-0c87-77cb-9867-613ae22e95ac", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 6, "textChars": 386, "nDataPoints": 12, "notes": "The slide highlights the trend of international pharma companies licensing innovative assets from Chinese biotech firms.", "elementsJson": [ "data_table", "logo_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:46.37+00", "seconds": 5.48, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/44", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-44", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.018, "w": 0.169, "x": 0.831, "y": 0.00182 }, "kind": "callout", "text": "NON-EXHAUSTIVE", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.37+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86190c4d-5993-49df-b792-871383cdd68b", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Deal size (USD Mn): 2,940", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-5ccd2d1ed76a", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.335, "x": 0.036, "y": 0.891 }, "kind": "source-note", "text": "Note: *Including upfront and milestone payments\nSource: Company websites, DXY, Cortellis Deal Intelligence, L.E.K. research and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.37+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "87a93335-d91d-430d-a27f-2497b7105bc5", "parentComponentId": null }, { "bbox": { "h": 0.695, "w": 0.964, "x": 0.036, "y": 0.208 }, "kind": "table", "text": "Select China pharmaceuticals out-licensing examples (2020-22 Aug, not exclusive)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.37+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a31a6497-0efa-4c73-9e40-fd9b2bc8e698", "parentComponentId": null }, { "bbox": { "h": 0.022, "w": 0.735, "x": 0.036, "y": 0.105 }, "kind": "title", "text": "... among which leading international pharma are actively licensing in Chinese innovative assets", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.37+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a9a38299-c786-4dcd-8302-2187561b394e", "parentComponentId": null }, { "bbox": { "h": 0.016, "w": 0.248, "x": 0.036, "y": 0.035 }, "kind": "title", "text": "Evolution of MNC China R&D strategy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.37+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "47a3b394-cad9-4dec-b07a-63fa92936333", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Deal size (USD Mn)", "numberRaw": "2,940", "numberKind": "plain", "actionTitle": "... among which leading international pharma are actively licensing in Chinese innovative assets", "calloutText": null, "numberScale": null, "numberValue": 2.94, "metricFamily": "market_size", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 45, "type": "evidence", "title": "The slide highlights a strategic shift in MNC R&D presence in China, moving towards collaborative incubation models.", "function": "illustrate_case", "rawType": "timeline", "block": null, "metadata": { "slideType": "timeline", "slideTypeCanon": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-0851-75eb-b758-ea2965e7739a", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 6, "textChars": 616, "nDataPoints": 5, "notes": "The slide highlights a strategic shift in MNC R&D presence in China, moving towards collaborative incubation models.", "elementsJson": [ "headline_text", "timeline_visual", "logo_grid", "photo" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:43.884+00", "seconds": 2.854, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/45", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-45", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "MNCs are shifting from establishing China R&D centers to China partnership centers or incubation centers to facilitate the collaboration with Chinese biopharmas", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-9915c513caad", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.95, "x": 0.03, "y": 0.25 }, "kind": "diagram", "text": "Timeline of MNC partnership and incubation center establishment from 2019 to 2022", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.884+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7c169584-9b3a-4f91-a060-4f697c8f53cd", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.9, "x": 0.05, "y": 0.3 }, "kind": "list", "text": "2019: J&J (JLABS), AstraZeneca (Wuxi I-Campus); 2020: BI (BI-ATLATL); 2021: Roche (Accelerator); 2022: Lilly (Incubator)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.884+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3391ec05-852f-4f77-a1c9-39679fc84423", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.03, "y": 0.9 }, "kind": "source-note", "text": "Source: Company websites, news, L.E.K. research and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.884+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86885b16-c9f2-4a72-835e-750e0a8f900e", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.9, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "MNCs are shifting from establishing China R&D centers to China partnership centers or incubation centers to facilitate the collaboration with Chinese biopharmas", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.884+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5a67628f-8c0f-4edb-8597-869d3319dd5f", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Evolution of MNC China R&D strategy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.884+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f695389e-c596-460f-b154-5a57a06d7e6c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "585bb3fd-2899-44da-a03c-03f9b22fb002", "evidence": "Chronological presentation of events on a horizontal axis.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 19:22:43.884+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 45, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 46, "type": "analysis", "title": "The slide uses a stacked bar chart to represent survey data (N=81) and includes two testimonial quotes from R&D leads.", "function": "summarize", "rawType": "industry_trends", "block": null, "metadata": { "slideType": "industry_trends", "slideTypeCanon": { "name": "Industry trends", "slug": "industry_trends", "status": "active", "canonId": "019de52d-0b1d-7705-a0e0-c663199cd1fa", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 83, "componentCount": 9, "textChars": 1194, "nDataPoints": 3, "notes": "The slide uses a stacked bar chart to represent survey data (N=81) and includes two testimonial quotes from R&D leads.", "elementsJson": [ "headline_text", "bar_chart_stacked", "quote_block" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:44.129+00", "seconds": 2.955, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/46", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-46", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": null, "kind": "callout", "text": "MNCs will collaborate more with Chinese companies through investment or incubation in order to benefit from local innovation capability", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": { "name": "Visual emphasis", "slug": "visual-emphasis", "status": "active", "bestFor": null, "canonId": "019dd9e1-474b-736b-a8eb-a794dd88241c", "version": 1, "bodyDocId": null, "description": "Drawing the eye to one element above the rest of the slide.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-b7a8496da974", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.42, "x": 0.037, "y": 0.21 }, "kind": "chart", "text": "Perspectives on R&D strategy of MNC pharmas (N=81)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "62cee4f4-0527-4760-92ca-85ef6900be9b", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Percent of respondents: 58%", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-bf6cacb5e10c", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.43, "x": 0.53, "y": 0.62 }, "kind": "quote", "text": "In a healthy ecosystem, different players can play different roles. Innovation from local companies in the ecosystem is valuable to MNCs because their expertise can be a complement to us.", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2de3cbf8-45f5-4f46-917d-ec8780c81e77", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.43, "x": 0.53, "y": 0.32 }, "kind": "quote", "text": "In the past, many MNCs established R&D centers in China; however, ROI was low mainly due to regulatory barriers... This co-existence model is expected to be more sustainable.", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": null, "subkind": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52c-fc21-71b6-9ac3-8266a64945e8", "version": 1, "description": null }, "framework": null }, "subkind": "testimonial", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "646d388d-8207-4f2d-99d1-f5737b6d1f19", "parentComponentId": null }, { "bbox": null, "kind": "quote", "text": "In a healthy ecosystem, different players can play different roles. Innovation from local companies in the ecosystem is valuable to MNCs because their expertise can be a complement to us. A win-win situation can be achieved ... - R&D Lead, a leading MNC pharma, Sept. 2022", "attrs": null, "canon": { "kind": { "name": "Quote", "slug": "quote", "status": "active", "canonId": "019de52c-f8fb-751e-8bc6-d58e2d59562a", "version": 1, "description": "Pull quote or testimonial." }, "tool": { "name": "Authority citation", "slug": "authority-citation", "status": "active", "bestFor": null, "canonId": "019dd9e1-49ae-7557-89ad-3fca70469b45", "version": 1, "bodyDocId": null, "description": "Quoting an authority figure, study, or precedent to lend weight.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:03+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cbf-b8fffd348eb5", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.75, "x": 0.037, "y": 0.89 }, "kind": "source-note", "text": "Note: *Survey question: Which of the following statements do you mostly agree with regarding MNCs’ R&D strategies within 5 years? Source: L.E.K. survey, interviews and analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ae7ed06f-c39d-4ffa-9872-f1f8dbd500eb", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.92, "x": 0.037, "y": 0.06 }, "kind": "title", "text": "Majority of respondents believe that MNC will further strengthen the partnerships with Chinese companies through investment and incubation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c02df1f2-0f63-473f-8211-a2b653cf67e2", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.037, "y": 0.033 }, "kind": "title", "text": "Evolution of MNC China R&D strategy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f6523889-f95f-4708-a1ac-441ae1939237", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Percent of respondents", "numberRaw": "58%", "numberKind": "percent", "actionTitle": "Majority of respondents believe that MNC will further strengthen the partnerships with Chinese companies through investment and incubation", "calloutText": "MNCs will collaborate more with Chinese companies through investment or incubation in order to benefit from local innovation capability", "numberScale": null, "numberValue": 58, "metricFamily": "survey_sentiment", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 47, "type": "setup", "function": "summarize", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "sparse", "densityScore": 8, "componentCount": 2, "textChars": 178, "nDataPoints": 0, "notes": null, "elementsJson": [ "bullet_list" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:43.055+00", "seconds": 1.775, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/47", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-47", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.497, "w": 0.497, "x": 0.038, "y": 0.218 }, "kind": "list", "text": "Context of clinical trial development in China\nFuture strategic trends of clinical trial development in China\nNext step questions\nResources and references\nAbout the authors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.055+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "921645f6-412d-4f67-afd1-bf1145828acf", "parentComponentId": null }, { "bbox": { "h": 0.044, "w": 0.085, "x": 0.038, "y": 0.144 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.055+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d8df0993-391c-4e8d-99dd-5bb26f19afc4", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 48, "type": "tension", "title": "The slide uses a lightbulb and question mark icon to signify strategic inquiry.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 6, "textChars": 1021, "nDataPoints": 0, "notes": "The slide uses a lightbulb and question mark icon to signify strategic inquiry.", "elementsJson": [ "headline_text", "bullet_list", "other" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:45.009+00", "seconds": 3.686, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/48", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-48", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.08, "x": 0.88, "y": 0.19 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.009+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ea08248-a2c1-4001-8595-3a267fd99d8c", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.85, "x": 0.037, "y": 0.68 }, "kind": "list", "text": "How to accelerate clinical development and registration in China in order to take the lead among competitors?\nHow to better cooperate with regulatory agency to advance the development of smart trial in China, especially virtual trial / DCT?\nWhat resources are needed to be successful? If partners are needed, what does a good partnership look like?", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.009+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86a23999-2bce-47bf-bd3d-ca706de176b6", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.85, "x": 0.037, "y": 0.25 }, "kind": "list", "text": "How to remain competitive in China and also leverage China’s resources to become regional / global leader?\nHow to find the development area that suits the company and at the same time, avoid homogeneous competition?\nHow to better embrace the trend of smart trials? What is the starting point?\nHow to better prioritize clinical trial destinations and communicate effectively with regulatory agencies when going overseas?\nHow should biotechs better partner or cooperate with Chinese biopharmas and MNCs on early innovation, clinical trial, market access and commercialization?", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.009+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "efff3967-7ea4-41a8-9ec8-90522384499b", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.65, "x": 0.037, "y": 0.095 }, "kind": "title", "text": "Industry can support and lead this China clinical trial transformation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.009+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c0cabc0f-21c0-4c12-938d-b4c85c890dfe", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.037, "y": 0.205 }, "kind": "title", "text": "For Chinese companies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.009+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dc8d66b4-9e90-4608-b1db-139f38bdfbd0", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.1, "x": 0.037, "y": 0.63 }, "kind": "title", "text": "For MNCs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.009+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e5ecc232-9b07-4522-824b-c6165f0fcd66", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 49, "type": "setup", "function": "summarize", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "sparse", "densityScore": 8, "componentCount": 2, "textChars": 178, "nDataPoints": 0, "notes": null, "elementsJson": [ "bullet_list" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:43.237+00", "seconds": 1.691, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/49", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-49", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.405, "w": 0.498, "x": 0.038, "y": 0.218 }, "kind": "list", "text": "Context of clinical trial development in China\nFuture strategic trends of clinical trial development in China\nNext step questions\nResources and references\nAbout the authors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.237+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4412ae99-be98-40fe-9dc3-47ecbb083fd1", "parentComponentId": null }, { "bbox": { "h": 0.043, "w": 0.106, "x": 0.038, "y": 0.143 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:43.237+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "425137bb-1121-4dc3-8996-758411517405", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 50, "type": "setup", "title": "The slide presents qualitative interview profiles and quantitative survey respondent demographics.", "function": "other", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 5, "textChars": 455, "nDataPoints": 18, "notes": "The slide presents qualitative interview profiles and quantitative survey respondent demographics.", "elementsJson": [ "bullet_list", "bar_chart_stacked", "paragraph" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:44.39+00", "seconds": 2.402, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/50", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-50", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.48, "x": 0.48, "y": 0.21 }, "kind": "chart", "text": "Survey respondent profile by company type, function, and job title", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.39+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "188f9964-695b-4502-bc0e-ce3c64681fff", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.36, "x": 0.04, "y": 0.21 }, "kind": "list", "text": "Interviewee profile: Chinese biopharmas / biotechs and MNC pharmas", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.39+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7d8c4091-665c-4e53-9906-ff621c9192eb", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "Survey respondents: 101", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:04+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cc0-0f95c1596237", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.5, "x": 0.04, "y": 0.91 }, "kind": "source-note", "text": "Note: *Others include financial investors and employees from medical device companies, hospitals and regulatory agencies", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.39+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "caf9bcf4-9e7e-4a4e-a1c4-95ddc8fd7f78", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "The report incorporates feedback from in-depth interviews with R&D leaders and management executives, and a survey of 101 market participants in China completed during October 2022", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.39+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ddc8c45b-91d6-4352-9f2e-bf742d56fe6b", "parentComponentId": null } ], "metrics": [ { "metricRaw": "Survey respondents", "numberRaw": "101", "numberKind": "plain", "actionTitle": null, "calloutText": null, "numberScale": null, "numberValue": 101, "metricFamily": "survey_sentiment", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 51, "type": "setup", "function": "summarize", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 7, "textChars": 837, "nDataPoints": 0, "notes": null, "elementsJson": [ "headline_text", "icon_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:44.717+00", "seconds": 2.678, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/51", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-51", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.73, "x": 0.24, "y": 0.79 }, "kind": "list", "text": "Company websites, EO Intelligence, Pharmaceutical Executive, Yicai", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.717+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a1722c6-65cc-4db6-9bce-40d777279d69", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.73, "x": 0.24, "y": 0.45 }, "kind": "list", "text": "Center for Drug Evaluation (CDE), Centre for Economics and Business Research, China Pharmaceutical Enterprises Association (CPEA), International Monetary Fund, National Bureau of Statistics, National Medical Products Administration (NMPA), Singapore Economic Development Board, The Pharmaceutical Research and Manufacturers of America, United Nations, World Bank, World Population Review", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.717+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6e885665-22b5-4d9d-8b56-8c827abaaffb", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.73, "x": 0.24, "y": 0.26 }, "kind": "list", "text": "Cortellis Deal Intelligence, DXY, Grand View, IQVIA, PharmaIntelligence, Pharmaprojects, Trialtrove, VBData, Yaozh", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.717+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a4fb17be-50ee-4f69-8c85-49e440e7ce92", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.73, "x": 0.24, "y": 0.67 }, "kind": "list", "text": "CMB China, Ping'An Securities, Sinolink Securities, Southwest Securities, SPDB International", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.717+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d3655034-828d-46cb-8afe-be9d5547f0ac", "parentComponentId": null }, { "bbox": { "h": 0.58, "w": 0.2, "x": 0.03, "y": 0.26 }, "kind": "list", "text": "Databases; Government / associations; Broker reports; Others", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.717+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff3c61db-d0bc-4d23-b35c-78d62c365a2b", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.94, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "We have also leveraged a wide range of secondary sources and L.E.K.’s China healthcare knowledge base", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.717+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f8f8477a-f1ac-4d0b-850e-f6b7f203de6b", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.19, "x": 0.03, "y": 0.21 }, "kind": "title", "text": "Secondary sources", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.717+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d37878aa-d94d-440f-8bab-a4b61344dd31", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 52, "type": "appendix", "function": "appendix", "rawType": "appendix", "block": null, "metadata": { "slideType": "appendix", "slideTypeCanon": { "name": "Appendix", "slug": "appendix", "status": "active", "canonId": "019de52d-0762-71f8-b564-89ab863301cc", "version": 1, "description": null }, "function": "appendix", "functionCanon": { "name": "Appendix", "slug": "appendix", "status": "active", "canonId": "019de52d-138d-750b-83c3-49b4bc7a7a38", "version": 1, "description": null }, "density": "sparse", "densityScore": 5, "componentCount": 2, "textChars": 112, "nDataPoints": 0, "notes": null, "elementsJson": [ "data_table" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:44.798+00", "seconds": 2.298, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/52", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-52", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "table", "text": "Acronym, Full English Name, Full Chinese Name columns for pharmaceutical and clinical trial terminology.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.798+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3583c3a6-0aa7-473c-af67-1e219dc3a73a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.1, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "Glossary", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.798+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6bcbe026-eda4-4748-b543-6c7ca9b8662b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 53, "type": "setup", "function": "front_matter", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 8, "componentCount": 2, "textChars": 178, "nDataPoints": 0, "notes": null, "elementsJson": [ "headline_text", "bullet_list" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:44.387+00", "seconds": 1.888, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/53", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-53", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.501, "w": 0.497, "x": 0.038, "y": 0.218 }, "kind": "list", "text": "Context of clinical trial development in China\nFuture strategic trends of clinical trial development in China\nNext step questions\nResources and references\nAbout the authors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.387+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bec2d1ad-9e34-4e2e-8804-563b561c30d5", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.075, "x": 0.038, "y": 0.143 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:44.387+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e051e499-58b1-4690-bc3a-04e1a27bf706", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 54, "type": "setup", "function": "other", "rawType": "appendix_disclosure", "block": null, "metadata": { "slideType": "appendix_disclosure", "slideTypeCanon": { "name": "Appendix disclosure", "slug": "appendix_disclosure", "status": "active", "canonId": "019de52d-07b2-7549-8e8b-932a19f6e616", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 48, "componentCount": 5, "textChars": 941, "nDataPoints": 0, "notes": null, "elementsJson": [ "paragraph", "logo_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:45.523+00", "seconds": 2.483, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/54", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-54", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.2, "x": 0.05, "y": 0.5 }, "kind": "image", "text": "PharmaDJ logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.523+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5a9f6dfc-fbb3-4576-9249-3ba6d42ad69c", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.58 }, "kind": "paragraph", "text": "Founded in 2014, PharmaDJ has expanded from a media outlet to a business intelligence platform including data-driven research, event organization and strategy consulting. Its areas of interest cover the entire drug life cycle, from early drug research, scientific translation to clinical development, commercial strategies, as well as market access strategies and public relations & communication strategies.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.523+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8afd9ae-4af8-467e-8327-6976b8837e55", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "paragraph", "text": "We would like to thank the co-organizer of ChinaTrials 14 – PharmaDJ – for their efforts in launching the extensive survey and interview program, as well as valuable contributions along the process of report writing. We would also like to express gratitude to all of our interviewees and survey respondents for their insightful industry knowledge that helped our content generation and in-depth analysis.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.523+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d6f2c170-5e76-4844-b277-4a1fa4e893ae", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "L.E.K. would like to acknowledge our co-sponsor – PharmaDJ’s great contribution for this report", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.523+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4f3f3a03-67d2-445b-be9f-6f180be732ad", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.05, "y": 0.45 }, "kind": "title", "text": "About our co-sponsor:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:45.523+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "91b33e5b-4bf6-4df6-947e-21f22af151ca", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 55, "type": "appendix", "title": "The slide serves as a corporate profile/introduction.", "function": "establish_context", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "balanced", "densityScore": 34, "componentCount": 5, "textChars": 333, "nDataPoints": 4, "notes": "The slide serves as a corporate profile/introduction.", "elementsJson": [ "headline_text", "map", "icon_grid", "logo_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:46.297+00", "seconds": 3.166, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/55", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-55", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.7, "x": 0.25, "y": 0.2 }, "kind": "image", "text": "World map with office locations", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Map", "slug": "map", "status": "active", "canonId": "019de52c-fe4d-77bd-b0a4-d72d58b9e5a4", "version": 1, "description": null }, "framework": null }, "subkind": "map", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.297+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "22d24e28-2221-40ad-a1d0-2d5f36f59d56", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.15, "x": 0.08, "y": 0.25 }, "kind": "list", "text": "Est. 1983\n19 offices\n~165 partners\n~1700 staff", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.297+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5de889c3-94d3-470f-a7c4-65ef2d2554a0", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.9, "x": 0.05, "y": 0.7 }, "kind": "list", "text": "Healthcare services\nMedical devices and technology\nDiagnostics\nHealthcare investing and financial sponsors\nSpecialty pharma / Drug delivery\nBio-pharma", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.297+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "677c3d2f-3e32-403c-ab58-de93af74c29c", "parentComponentId": null }, { "bbox": null, "kind": "metric", "text": "staff: ~1700", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": { "name": "Quantification", "slug": "quantification", "status": "active", "bestFor": null, "canonId": "019dd9e1-47ab-72ce-a079-aab1f5299e88", "version": 1, "bodyDocId": null, "description": "Translating a claim into numbers, charts, or tables.", "familyLabel": null }, "subkind": null, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-04-24 13:18:05+00", "model": "or:google/gemini-3.1-flash-lite-preview", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "019dd951-c7ca-701b-9cc0-871a0b4fb99b", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.86, "x": 0.037, "y": 0.095 }, "kind": "title", "text": "L.E.K. Consulting is a global strategy consulting firm with significant coverage in healthcare", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.297+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c2e6f15a-7e08-40a6-a997-6e8ac9b9b0bd", "parentComponentId": null } ], "metrics": [ { "metricRaw": "staff", "numberRaw": "~1700", "numberKind": "plain", "actionTitle": "L.E.K. Consulting is a global strategy consulting firm with significant coverage in healthcare", "calloutText": null, "numberScale": null, "numberValue": 1700, "metricFamily": "other", "numberCurrency": null } ], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 56, "type": "appendix", "title": "This is a resource/reference slide listing various publications.", "function": "other", "rawType": "appendix", "block": null, "metadata": { "slideType": "appendix", "slideTypeCanon": { "name": "Appendix", "slug": "appendix", "status": "active", "canonId": "019de52d-0762-71f8-b564-89ab863301cc", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 11, "textChars": 762, "nDataPoints": 0, "notes": "This is a resource/reference slide listing various publications.", "elementsJson": [ "screenshot", "other" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:46.502+00", "seconds": 3.274, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/56", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-56", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.95, "x": 0.03, "y": 0.2 }, "kind": "image", "text": "Grid of 8 report covers with titles in English and Chinese", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "63417c5a-73ad-4892-9877-080e4385827b", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.43, "y": 0.68 }, "kind": "paragraph", "text": "How Pharma Sustainability Commitments Are Affecting Contract Manufacturers", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "255ed7b4-113a-4791-98ad-fd9c79abf88b", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.43, "y": 0.22 }, "kind": "paragraph", "text": "Expanding Into Asia-Pacific: Life Sciences Opportunities and Strategies for Success", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3f65e23a-00bd-48f9-a581-dce019c108f5", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.75, "y": 0.45 }, "kind": "paragraph", "text": "Opportunities and Patient Insights into the China Oncology Market", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "71c9bb4f-a056-4da5-8f03-28bc80b43204", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.75, "y": 0.22 }, "kind": "paragraph", "text": "Using Real-World Data to Optimize Pharma Pricing in China", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "81c15c5a-9800-403e-b9ef-0b25df8775b7", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.12, "y": 0.68 }, "kind": "paragraph", "text": "Trends in Pharma Asset Licensing and Deal Terms: A Survey of Key Decision-Makers", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ce81f6d-8ee0-4e48-be15-3b51e49e34d0", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.12, "y": 0.22 }, "kind": "paragraph", "text": "Looking Ahead in Biopharma: Key Trends Impacting the Industry", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9308e308-6628-4469-b4e4-7c6aee9c97b8", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.43, "y": 0.45 }, "kind": "paragraph", "text": "Gene Therapy: Competitive Dynamics and Commercial Implications", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c421683f-1316-46b6-a337-56d21c923da7", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.75, "y": 0.68 }, "kind": "paragraph", "text": "Maximizing Oncology Success Through World-Class Guideline and Compendia Strategies", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e0996a03-cb2c-44af-b5a5-6a1f6131d4a2", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.12, "y": 0.45 }, "kind": "paragraph", "text": "The Hub-and-Spoke Model: An Emerging Biopharma Trend", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ffea1e48-49ff-4482-98b9-6abde406d6bf", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.85, "x": 0.03, "y": 0.1 }, "kind": "title", "text": "More market leading insights and thought leadership are available on the LEK.com website", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.502+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7c12c04a-60ad-4834-9d8a-3a5234f8bda5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 57, "type": "appendix", "function": "other", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 37, "componentCount": 7, "textChars": 148, "nDataPoints": 0, "notes": null, "elementsJson": [ "headshot", "map", "icon_grid" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:46.503+00", "seconds": 3.205, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/57", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-57", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.18, "w": 0.08, "x": 0.037, "y": 0.211 }, "kind": "image", "text": "Evan Zeng", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "46a51334-172a-4c11-83e9-6df98875b552", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.08, "x": 0.309, "y": 0.525 }, "kind": "image", "text": "Justin Wang", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7b4375b6-9d3a-4b57-a905-9ae53b30df40", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.08, "x": 0.037, "y": 0.525 }, "kind": "image", "text": "Jiawei Qin", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dee0baac-fde6-4d56-a993-a59614c0375a", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.08, "x": 0.309, "y": 0.211 }, "kind": "image", "text": "Helen Chen", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f73dacc2-c41b-4e94-a41c-e2b863a83752", "parentComponentId": null }, { "bbox": { "h": 0.235, "w": 0.365, "x": 0.594, "y": 0.405 }, "kind": "image", "text": "Global office locations", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Map", "slug": "map", "status": "active", "canonId": "019de52c-fe4d-77bd-b0a4-d72d58b9e5a4", "version": 1, "description": null }, "framework": null }, "subkind": "map", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "658947e8-16ba-499a-a589-2d6a1939571e", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.42, "x": 0.143, "y": 0.211 }, "kind": "list", "text": "Contact details for Evan Zeng, Helen Chen, Jiawei Qin, and Justin Wang", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1545a000-b002-4309-8691-5ad987f33659", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.181, "x": 0.037, "y": 0.103 }, "kind": "title", "text": "Connect with us", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aba655a4-a649-46b0-84b9-484fff8ca1ec", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 58, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 5, "textChars": 2325, "nDataPoints": 0, "notes": null, "elementsJson": [ "paragraph" ], "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 19:22:46.718+00", "seconds": 3.319, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019dd923-5ca1-7489-b638-42055a53b541/58", "deck": "/decks/019dd923-5ca1-7489-b638-42055a53b541", "deckAnchor": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-58", "deckJson": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json" }, "components": [ { "bbox": { "h": 0.585, "w": 0.924, "x": 0.038, "y": 0.257 }, "kind": "disclaimer", "text": "This document is intended to provide information and is for illustration purposes only. Accordingly, it must be considered in the context and purpose for which it has been prepared. It cannot be relied upon by any recipient. In accepting this document, you agree that L.E.K. Consulting Ltd and their affiliates, members, directors, officers, employees and agents (L.E.K.) neither owe nor accept any duty or responsibility or liability to you or any third party, whether in contract, tort (including negligence), or breach of statutory duty or otherwise, howsoever arising, in connection with or arising from this report or the use you or any third party make of it. L.E.K. shall not be liable to you or any third party in respect of any loss, damage or expense of whatsoever nature that is caused by your or any third party's reliance on or for any use you or any third party may choose to make of the report, which you accept is at your or their own risk. This report is based on information available at the time this report was prepared and on certain assumptions, including, but not limited to, assumptions regarding future events, developments and uncertainties, and contains 'forward-looking statements' (statements that may include, without limitation, projected market opportunities, strategies, competition, expected activities and expenditures, and at times may be identified by the use of words such as \"may\", \"could\", \"should\", \"would\", \"project\", \"believe\", \"anticipate\", \"expect\", \"plan\", \"estimate\", \"forecast\", \"potential\", \"intend\", \"continue\" and variations of these words or comparable words). L.E.K. is not able to predict future events, developments and uncertainties. Consequently, any of the forward-looking statements contained in this report may prove to be incorrect or incomplete, and actual results could differ materially from those projected or estimated in this report. L.E.K. does not undertake any obligation to update any forward-looking statements for revisions or changes after the date of this report, and L.E.K. does not make any representation or warranty that any of the projections or estimates in this report will be realised. Nothing contained herein is, or should be relied upon as, a promise or representation as to the future.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.718+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5c25a41e-15d6-4eb6-be2f-b214b88a8d95", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.1, "x": 0.879, "y": 0.904 }, "kind": "image", "text": "LEK", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.718+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d0b8091e-df92-4e17-ad0f-090308e5840b", "parentComponentId": null }, { "bbox": { "h": 0.022, "w": 0.015, "x": 0.038, "y": 0.938 }, "kind": "other", "text": "58", "attrs": null, "canon": { "kind": { "name": "Other", "slug": "other", "status": "active", "canonId": "019de52c-fa90-743c-8bf6-20d1fbe82b6d", "version": 1, "description": "Fallback when no canonical kind applies." }, "tool": null, "subkind": { "name": "Unclassified", "slug": "unclassified", "status": "active", "canonId": "019de52d-05ca-77db-81fb-db7d4234bbc0", "version": 1, "description": null }, "framework": null }, "subkind": "unclassified", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.718+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b4d9d3c4-6abe-4bfc-9145-c5b5cfdd41b7", "parentComponentId": null }, { "bbox": { "h": 0.015, "w": 0.17, "x": 0.809, "y": 0.96 }, "kind": "source-note", "text": "© L.E.K. Consulting Limited 2022", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.718+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "805d277a-4b28-4ac9-893e-99d37724e064", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.185, "x": 0.038, "y": 0.105 }, "kind": "title", "text": "Important notice", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 19:22:46.718+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f17d0b8c-2f69-40df-8a80-2c93a0934637", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 1, "to": 5, "label": "Situation & Context", "description": "The report provides an overview of the clinical trials landscape in China, including key economic and healthcare indexes." }, { "from": 6, "to": 11, "label": "Problem & Complication", "description": "The report discusses the challenges facing China's clinical development, including COVID-19 uncertainties and funding challenges." }, { "from": 12, "to": 20, "label": "Solution & Approach", "description": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies." } ], "loops": [ { "from": 11, "to": 20, "label": "Cost Of Inaction", "description": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?" } ] }